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Abstract 
Cancer is known as one of the leading causes of death in the world. Recent years have 
witnessed substantial progress in understanding tumor heterogeneity and the process of tumor 
progression; however, the entire step-wise process of the transition of tumors from benign to 
metastatic state remains poorly understood. In this dissertation, I conducted genome- and 
transcriptome-sequencing analyses for the tumorigenesis process to reveal the entire 
mechanisms of the tumor progression. 
 In the genome-sequencing study, I performed a prospective analysis by employing an 
experimental carcinogenesis mouse model to systematically understand the evolutionary 
process of tumors. Collaborators surgically collected a part of a lesion of each tumor and 
followed the progression of these tumors in vivo over time. I conducted the comparative 
time-series analysis of the genomes of tumors with different fates, i.e., those that eventually 
metastasized and regressed. The results suggested that these tumors acquired and inherited 
different mutations. Despite the occurrence of an intra-tumor selection event for malignant 
alteration during the transformation from early- to late-stage papilloma, the fate 
determination of tumors might be determined at an even earlier stage. 
 While the genome-sequencing enables us to analyze the genomic mutations, 
transcriptome-sequencing technology is widely used to comprehensively detect and quantify 
cellular gene expression. Numerous analytical methods have been proposed for identifying 
differentially expressed genes (DEGs) between paired samples such as tumor and control 
specimens, but few studies have reported methods for analyzing differential expression under 
multiple conditions as my research target, the step-wise process of the tumor progression. In 
the transcriptome-sequencing study, I propose a novel method, DEclust, for differential 
expression analysis among more than two matched samples from distinct tissues or 
conditions. As compared to conventional clustering methods, DEclust more accurately 
extracts statistically significant gene clusters from multi-conditional transcriptome data. As a 
result of applying my method to the cancer transcriptome analysis, DEclust extracted 16 gene 
clusters whose expression patterns were discriminative in the process of the tumor 
progression; moreover, the genes which were belonging to each of these clusters were 
significantly enriched for biological functions. 
 Through the genome and transcriptome studies, I gave insights of the evolutional process in 
the tumors over time and the gene clusters whose expression patterns were discriminative in 
the process of the tumor progression. Examples of the research that directly analyzes the 
process of tumor progression are rare; hence, my results are meaningful and I consider that it 
is necessary to advance such a direct approach to reveal the entire process of cancer 
progression. 
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Chapter 1 
Introduction 
Cancer is known as the leading cause of death in the world, with approximately 14 million 
new cases and more than 8 million deaths occurring in 2012 worldwide (Torre et al., 2015). 
Cancer is a result of genomic disorders represented by DNA mutations that typically lead to 
loss of DNA repair function and gain of abnormal proliferation function. Numerous reports 
on the process of malignant alterations suggest that benign tumors progress in a stepwise 
fashion while acquiring driver and passenger mutations, which eventually invade surrounding 
tissues to finally migrate to distant tissues (Fearon and Vogelstein, 1990; Hanahan and 
Weinberg, 2011; Greaves and Maley, 2012; Vogelstein et al., 2013; McGranahan et al., 2015; 
Tomczak, Czerwińska and Wiznerowicz, 2015); however, the entire process of tumor 
progression, from a benign to metastatic state, is still poorly understood. 
 In this dissertation, I present genome and transcriptome studies for the tumorigenesis 
process to understand the entire mechanisms of the tumor progression. First, I performed a 
prospective genome-sequencing analysis by employing an experimental carcinogenesis for 
mice. My collaborators surgically collected a part of a lesion of each tumor and followed the 
progression of these tumors in vivo over time. I performed a time-series analysis of these 
tumors to reveal the accumulation process of genomic mutations over time, and also a 
comparative analysis to reveal the differences between tumors with different fates, e.g., those 
that eventually metastasized and regressed (Aoto et al., 2018). Second, I performed 
transcriptome-sequencing to analyze the transcriptome dynamics in the tumorigenesis process. 
For this purpose, I first developed a novel analytical method to handle multi-conditional, such 
as time-series, transcriptome data. Next, I applied the proposed method for the tumors 
obtained from the experimental carcinogenesis to extract gene clusters whose expression 
patterns were discriminative in the tumorigenesis process (Aoto et al., 2017). I aimed to 
clarify the tumorigenesis process through understanding each of the omics layers, genome 
and transcriptome, by conducting above two studies. The genome analysis has a potential to 
reveal the intra-tumor structure changing with time. The transcriptome analysis also has a 
potential to identify the genes with characteristic expression patterns in the process of 
tumorigenesis. 
 This dissertation is organized as follows. In this chapter, I introduce some basic information 
about cancer and the originality of my studies briefly. In Chapter 2, I describe the results of 
genome-sequencing analysis. In Chapter 3, I describe the results of transcriptome-sequencing 
analysis. Finally, the summary of my studies and also discussion of future prospects are 
described in Chapter 4. 
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1.1 Cancer 
As described above, cancer is one of the fatal diseases worldwide. Recent trends of cancer 
disease are summarized in a fact sheet published by the World Health Organization (WHO) in 
February 2018 (Torre et al., 2015). Cancer is the second leading cause of death globally, and 
there are several known risk factors such as high body mass index, low fruit and vegetable 
intake, lack of physical activity, tobacco use, and alcohol use. Cancer can affect any part of 
the body. The initial event of the development of cancer is genomic disorders such as DNA 
mutations. The DNA mutations that induce the aberrant growth or the defection in the DNA 
repair function causing an initial tumor cell. The aberrant growth promotes the tumorigenesis, 
and the defection in the DNA repair function affects genomic instability of the cancer genome. 
Thus, the tumor cell proliferates abnormally to form benign tumor, and the benign tumor 
progresses stepwise accompanied by random acquisition of further somatic mutations owing 
to genomic instability (Fig. 1.1). Eventually, the tumor invades surrounding tissues to finally 
metastasizes to distant tissues (Fearon and Vogelstein, 1990; Vogelstein et al., 2013). In most 
cases except for the familial cancers, somatic mutations cause cancers. Recent studies have 
reported that the somatic mutations not only cause the initial tumor cell, but also drive tumor 
progression. The somatic mutations that directly drive tumor progression are called as “driver 
mutations”, and the somatic mutations that accidentally occur in the process of tumor 
progression are called as “passenger mutations”. 
 
 
Figure 1.1. Stepwise process of cancer progression. In the process of cancer progression, the 
tumor acquires abnormal biological functions in a sequential manner. The tumor eventually 
invades the surrounding tissues and migrates to distant tissues. 
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 Recently, high-throughput sequencing technology has been used for genome-wide cancer 
analysis for a comprehensive understanding of the genomic mutations, gene expression levels, 
and epigenetic status (Shendure and Ji, 2008; Metzker, 2010). Cancer genome studies that 
aim to detect driver gene mutations and the cancer transcriptome studies that detect abnormal 
gene expression have been actively conducted to understand the cause of malignant alteration 
(Tomczak, Czerwińska and Wiznerowicz, 2015). These previous researches identified that 
there are various genes which drive tumor development, while multiple drivers are necessary 
for the malignant transformation, and each case is caused by different driver events 
(Martincorena and Campbell, 2015). This difference between tumor cases is known as 
“inter-tumor heterogeneity”. This inter-tumor heterogeneity increases the difficulty of cancer 
therapy to which different treatments are required for each case (Burrell et al., 2013; 
Vogelstein et al., 2013). 
 While a single original tumor cell proliferates and expands to form a tumor, each tumor cell 
randomly acquires genomic mutations due to the genomic instability; therefore, there is 
genetic diversity among tumor cells (Fig. 1.2) (Greaves and Maley, 2012). This genetic 
diversity between tumor cells is known as “intra-tumor heterogeneity”, and the cell 
population with the same genetic background is called as a “sub-clone”. The genetic diversity 
of tumor cells generates the physiological diversity and difference in therapeutic sensitivity 
among tumor cells. Accordingly, the intra-tumor heterogeneity is considered to be the most 
critical cause of treatment resistance and the recurrence of cancer (Greaves and Maley, 2012; 
Swanton, 2012; Burrell et al., 2013). Furthermore, the intra-tumor heterogeneity is also 
considered to contribute to the cancer progression. The environment inside and outside the 
tumor is harsh for tumor cells to survive and it is changing continually. At the beginning of 
the tumorigenesis, the tumor cells have to evade the immune response from surrounding 
tissue. After establishment of a benign tumor, it is necessary to withstand the nutritional 
deficiency and the oxidative stress which are the results of the abnormal proliferation 
(Hanahan and Weinberg, 2011). Only tumor cells that could acquire the traits that enable to 
overcome these adversities can survive and become malignant; thus, by considering the 
adversities as selection pressure, evolutional progression models have been proposed and 
discussed aggressively (Martincorena and Campbell, 2015; Davis, Gao and Navin, 2017). 
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Figure 1.2. Intra-tumor heterogeneity and evolutional process in tumors. The original tumor 
cell proliferates and expands to form a tumor. The tumor cells randomly acquire the genomic 
mutations and form a malignant tumor with genetic diversity. 
 
 Through the existing researches to date, the understanding of the inter-/intra-tumor 
heterogeneity has been boosted; however, the entire process of the tumor progression is still 
unknown because most of cancer researches use specimens that have already become 
malignant. Hence, I conducted genome and transcriptome analysis to reveal the whole 
process of tumor progression, from a benign to metastatic state. 
1.2 High-throughput DNA sequencing 
High-throughput DNA sequencing technologies have been popularized since the 2000s 
(Metzker, 2010). While several approaches have been proposed for high-throughput DNA 
sequencing, either approach has adopted massively parallel sequencing of DNA fragments. In 
usual cases, an input of DNA sequencer is fragmented DNAs obtained by sonication or 
enzyme reaction for the genomic DNA. One side (single-end) or both sides (paired-end) of 
the DNA fragments are sequenced. The cDNA that are obtained from the reverse transcription 
reaction for the RNA is also available for high-throughput sequencing. The throughputs and 
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sequencing lengths are different among sequencing platforms. For instance, the HiSeq series 
from Illumina Inc., the most prevalent technology, allows up to five billion parallel 
sequencing and ~300bp determination for each DNA fragment (https://jp.illumina.com/), and 
the Illumina MiSeq, I adopted, implements 25 million parallel sequencing reactions and 
~600bp read length. The determined sequences are termed as “reads”. These reads are often 
mapped against a known (reference) genomic sequence to detect DNA mutations or gene 
expression. 
 There are several applications to solve various research problems. The whole genome 
sequencing (WGS) and whole transcriptome sequencing (WTS) technologies provide whole 
genomic-scale nucleotide sequence information of specimens. Moreover, targeted sequencing 
technology has been also established which enables to analyze specific genomic regions such 
as the exons, promoter regions, and so on. 
1.3 Cancer genome analysis 
As described above, the cause of cancer disease is genomic disorders. In this decade, the 
cancer genome analysis has been widely conducted by using high-throughput sequencing 
technologies and that has brought a lot of discoveries. There are several types of genomic 
mutations ranging from local mutation on the genomic sequence such as single-nucleotide 
variants (SNVs) and short-insertions / deletions (indels) to chromosomal-scale mutations 
such as structural variants (SVs) and copy number variations (CNVs). To detect these 
genomic mutations, the sequenced short-reads are simultaneously mapped against the 
reference genome sequence (Fig. 1.3). Many analytical methods have been proposed: BWA 
(Li and Durbin, 2009) and bowtie2 (Langmead and Salzberg, 2012) are the standard tools for 
mapping, and MuTect2 (Cibulskis et al., 2013), Strelka (Saunders et al., 2012), VarScan2 
(Koboldt et al., 2012), SomatiSniper (Larson et al., 2012), and LoFreq (Wilm et al., 2012) 
are standardly used to detect somatic mutations in cancer. 
 
Figure 1.3. Detection of the genomic mutations by using the sequenced short-reads. 
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Mainly, two methods are adopted for the analysis of intra-tumor heterogeneity (Fig. 1.4). 
The first method is single-cell sequencing. Single-cell sequencing is appropriate for the 
cancer genome studies because it enables to analyze each tumor cell separately; however, it is 
impractical for comprehensive analysis of a large number of tumor cells composing a single 
tumor mass. The second method is bulk sequencing. The bulk sequencing is a method for 
comprehensive analysis of a whole tissue. In the process of sample preparation for the bulk 
sequencing, genomic DNAs are extracted from the tissue without dividing into cells. The 
extracted genomic DNAs are fragmented and then are randomly chosen to sequence. 
Although the information on each cell is lost, the bulk sequencing method enables a 
comprehensive detection of the somatic mutations and an estimation of the prevalence of the 
mutations in a tumor. For the estimation of the prevalence of each mutation, a variant allele 
frequency (VAF) is calculated from the mapping results. The VAF is defined as a proportion 
of the mutation-supporting reads per the entire reads mapped to the genomic position; then, it 
is considered as a pseudo-probability of the prevalence of the mutant cells in a tumor. The 
VAFs are widely used for the estimation of the intra-tumor structure, and several methods 
have also been proposed to predict the intra-tumor sub-clonal structure from the VAFs (Miller 
et al., 2014; Roth et al., 2014). Moreover, the targeted sequencing technology, which can 
concentrate on the acquired sequencing reads in specific genomic regions, is used in 
conjunction with the bulk sequencing to estimate the VAFs more accurately and to detect low 
frequency mutations. 
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Figure 1.4. Single-cell sequencing and bulk sequencing methods. The single-cell method 
provides nucleotide sequence information for each cell separately. The bulk method enables 
to analyze whole or a part of a tissue. When the research target is a whole tissue or a part of 
the tissue, the bulk sequencing method is usually adopted. Although the sequence information 
from bulk approach cannot decompose into cell units, the mutated positions and the variant 
allele frequencies (VAFs) of the mutated positions are available. 
 
Recent cancer genome studies, represented by The Cancer Genome Atlas (TCGA), have 
gradually revealed the mutational landscapes of various types of tumors. The mutation 
burden and the driver mutations have been extensively investigated (Tomczak, Czerwińska 
and Wiznerowicz, 2015). The correlation between the substitution patterns of the somatic 
mutations and the mutagens has been reported (Alexandrov et al., 2013). For the 
understanding of the intra-tumor heterogeneity, recent studies adopt a multi-region 
sequencing. In these studies, single malignant tumor was divided into multiple parts, and 
sequencing analysis was performed for each part of the same tumor. As the results, they 
reported an intra-tumor phylogenetic structure and suggested the evolutional process in tumor 
(Gerlinger et al., 2012). 
 Despite these advances in the general understanding of inter-/intra-tumor heterogeneity and 
the process of tumor progression, the entire evolutionary process of tumors, from a benign to 
metastatic state, is still poorly understood. In the genome-sequencing study, I conducted a 
prospective cancer genome study to track the transitions from an early benign tumor to the 
metastatic tumor by using an experimental carcinogenesis system. 
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1.4 Cancer transcriptome analysis 
While the genome sequencing and subsequent analysis enables identification of genomic 
mutations, high-throughput RNA sequencing (RNA-Seq) technology facilitates 
comprehensive detection and quantification of the gene expression in cells and tissues (Wang, 
Gerstein and Snyder, 2009). For RNA-Seq, reverse transcription reaction is performed for 
extracted template RNAs to be converted to cDNAs. The sequenced short-reads, yielded by 
the massively parallel sequencing of the ends of cDNA fragments, are mapped to the 
reference genome to quantify the gene expression levels. To quantify the gene expression 
levels, most of the analytical methods count the number of reads mapped to each gene region 
and normalize the read counts to comparable values. The most naïve normalization method is 
to divide the number of mapped reads by the total number of reads to correct the difference in 
the total number of reads between samples. Although, the gene expression is constantly 
fluctuating, it is considered as a stochastic process (Elowitz et al., 2002); therefore, a 
statistical treatment is required for the quantification of gene expression levels including the 
read count normalization. Many analytical methods not only to quantify the gene expression 
levels but also to statistically compare the expression levels between different experimental 
conditions have been proposed. DESeq2 (Love, Huber and Anders, 2014), edgeR (Robinson, 
McCarthy and Smyth, 2010), and Cufflinks (Trapnell et al., 2013) are widely used for gene 
expression analysis. For cancer transcriptome studies, these tools have been used to detect 
differentially expressed genes (DEGs) in tumor samples (Rhodes et al., 2004). The DEGs in 
tumor samples are the candidates of biomarkers. The existing DEG detection tools can handle 
a pair of experimental conditions such as case and control samples, therefore they are 
appropriate for most of the previous cancer studies that compare gene expression levels 
between malignant tumors and normal tissues. In contrast, an analytical method applicable to 
multi-condition analysis is required for my study to reveal the entire process of tumor 
progression; however, few methods have been proposed and there is no single standard 
method. Accordingly, I focused on the clustering analysis that is one of the multivariate 
analysis methods. 
 For the multivariate analysis of the transcriptome data, clustering analysis according to gene 
expression patterns is widely used for patient subtype classification (van ’t Veer et al., 2002), 
and for searching the biological functions that are abnormally expressed in lesion sites 
(Prensner et al., 2011). To cluster the genes whose expression patterns are similar to each 
other, it is required to measure the similarity between genes or gene clusters. Commonly, 
Euclidean distance, Pearson’s correlation, and cosine similarity are used for the similarity 
measure between genes, and the average, complete linkage, and single linkage methods are 
used for the similarity measure between gene clusters (D’haeseleer, 2005). Since these 
existing similarity measures do not include statistical processing and are based on only the 
mean of expression levels, existing clustering methods cannot discriminate significant gene 
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expression differences from noises. Hence, in transcriptome-sequencing study, I first 
developed a novel clustering method based on statistical tests to extract significant gene 
clusters from multi-conditional transcriptome data. Second, I performed RNA-Seq for benign, 
malignant, and metastatic tumors obtained from the experimental carcinogenesis of mice. 
Finally, I applied the proposed method to the acquired RNA-Seq data to extract 
discriminative gene clusters in the process of tumor progression. 
  
 10 
 
Chapter 2 
Time-series analysis of tumorigenesis in a murine skin 
carcinogenesis model 
In this chapter, I show the results of genome analysis for the tumorigenesis process (Aoto et 
al., 2018). 
 Recent years have witnessed substantial progress in understanding tumor heterogeneity and 
the process of tumor progression; however, the entire process of the transition of tumors from 
benign to metastatic state remains poorly understood. In the present study, I performed a 
prospective cancer genome-sequencing analysis by employing an experimental 
carcinogenesis mouse model to systematically understand the evolutionary process of tumors. 
The collaborators surgically collected a part of a lesion of each tumor and followed the 
progression of these tumors in vivo over time. I conducted the comparative time-series 
analysis of the genomes of tumors with different fates, i.e., those that eventually metastasized 
and regressed. It suggested that these tumors acquired and inherited different mutations. 
Despite the occurrence of an intra-tumor selection event for malignant alteration during the 
transformation from early- to late-stage papilloma, the fate determination of tumors might be 
determined at an even earlier stage. 
2.1 Background 
2.1.1 Intra-tumor heterogeneity 
As described in Chapter 1, cancer is a result of genomic disorders such as DNA mutations. 
Recent studies focusing on the intra-tumor environment suggest a polyclonal structure of 
tumors due to genomic instability (Greaves and Maley, 2012; Swanton, 2012; Burrell et al., 
2013). Although tumors initially form from a single cell type, as each tumor cell randomly 
acquires somatic mutations and then proliferates, the polyclonal cell population is formed 
based on the different genetic background among tumor cells (Greaves and Maley, 2012; 
Swanton, 2012; Burrell et al., 2013). This genetic diversity of tumor cells generates the 
physiological diversity and difference in therapeutic sensitivity among tumor cells. 
Accordingly, the polyclonal structure of tumors is considered to be the most critical cause of 
treatment resistance and the recurrence of cancer (Greaves and Maley, 2012; Swanton, 2012; 
Burrell et al., 2013). 
 More recently, the polyclonal structure of tumors has been addressed under the field termed 
“intra-tumor heterogeneity”, which has emerged as an essential aspect required for disclosing 
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the whole landscape of tumor progression and delineating the specific causes of resistance to 
cancer treatment. To best understand the full spectrum of intra-tumor heterogeneity, 
evolutionary analysis has been performed using multi-region samples, which obtained from 
the multiple sites of one malignant tumor, and/or the primary and metastatic tumors from the 
same animal; accordingly, several models have been proposed to explain the process of tumor 
progression and the origin of tumors (Gerlinger et al., 2012; Martincorena and Campbell, 
2015; Jamal-Hanjani et al., 2017; McGranahan and Swanton, 2017). An adaptive (Darwinian) 
tumor progression model was suggested by which only certain sub-groups (i.e., sub-clones) 
that could gain advantageous traits to survive would remain in the tumor environment. In the 
process of stepwise cancer progression, tumors have to overcome several barriers such as the 
lack of nutrients, immune response from the surrounding tissues, and lack of the growth 
space, among others (Hanahan and Weinberg, 2011). These barriers impose a type of 
selection pressure for tumor cells so that only those that are best adapted to the given tumor 
environment will survive to proliferate and will acquire various mutations in the process to 
lead to intra-tumor heterogeneity. Such intra-tumor heterogeneity is considered to contribute 
to the diversity in treatment sensitivity and the sustainable progression of tumors (Greaves 
and Maley, 2012; Swanton, 2012; Burrell et al., 2013; McGranahan and Swanton, 2017). In 
contrast, the neutral evolution theory of tumor progression proposes that tumor cells are 
derived from an initial malignant cell such as a cancer stem cell that neutrally expands with 
random mutations, leading to intra-tumor heterogeneity (Williams et al., 2016; McGranahan 
and Swanton, 2017). 
 Moreover, several hypotheses have been proposed to explain the origin of tumors, including 
a founder cancer stem cell that already possesses multiple driver mutations and then rapidly 
grows and forms a tumor via the acquisition of new driver (trigger) mutations, or an initial 
driver mutation develops that causes an undetectable tumor, which gradually grows in size 
owing to the acquisition of new driver mutations (Martincorena and Campbell, 2015). 
Despite these advances in the general understanding of inter-/intra-tumor heterogeneity and 
the process of tumor progression, the entire evolutionary process of tumors, from a benign to 
metastatic state, is still poorly understood. Understanding the process of tumor evolution over 
time is expected to improve the confidence of early diagnostics and prognostic predictions. 
However, to date, the majority of cancer studies use specimens that have already transitioned 
to malignancy, and research based on tracking the transitions from an early benign tumor to 
the metastatic tumor is relatively limited. 
2.1.2 Research purpose and murine skin carcinogenesis model 
Given the above background, I have begun to address this issue with a prospective cancer 
study with the aim of systematically understanding the evolutionary process of tumors. 
Toward this end, I and my collaborators have employed an experimental carcinogenesis 
mouse model, which promotes the formation of squamous cell carcinoma (SCC) on the back 
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skin of the mice. The collaborators performed a classical two-stage carcinogenesis protocol to 
chemically induce the SCCs for mice using 7,12-dimethylbenz(a)anthracene (DMBA) and 
12-O-tetradecanoylphorbol-13-acetone (TPA). In essence, the collaborators surgically 
collected a part of a lesion of each papilloma that formed, and followed the progression of 
each of these tumors in vivo over time. These identical tumors were repeatedly sampled at 
different growth stages to implement a time-series analysis from benign to metastatic tumors. 
During this sampling process, I and collaborators observed various fates of the tumors: some 
became malignant, others remained benign, whereas others regressed. Therefore, I decided to 
focus on these intra-tumor changes over time as well as on the inter-tumor differences 
according to comparison of tumors with different fates. To achieve a mechanistic 
understanding of these differences, I performed high-throughput deep-targeted genome 
sequencing for two tumor series that were collected from the same mouse, one that eventually 
became malignant and another that regressed, and conducted comparative time-series 
analysis to understand the evolutionary process of tumors and the factors that determine 
tumor fates. 
 SCC is one of the most common cancers in Caucasian populations, and the prognosis of 
metastatic SCC is extremely poor (Huang and Balmain, 2014). The DMBA-induced SCC 
model is one of the most commonly used in vivo models and is widely used for studying the 
mechanisms of metastasis (Ruddell et al., 2008), which can be applied to both human and 
mouse cancers (Balmain and Yuspa, 2014; Huang and Balmain, 2014). High-throughput 
genome sequencing analysis has previously been conducted for DMBA-induced mouse skin 
SCCs (McCreery et al., 2015; Nassar et al., 2015). Nassar et al. (Nassar et al., 2015) 
investigated the mutational landscape of DMBA-induced SCCs to reveal the substitution 
patterns of the DMBA-induced somatic mutations and the genes recurrently mutated in this 
experimental model. McCreery et al. (McCreery et al., 2015) performed phylogenetic 
analysis for the benign, malignant, and metastatic tumors obtained from the same mouse to 
reveal the origins of metastases and to indirectly predict the process of tumor evolution. 
Although these studies reported significant results, almost all of the DMBA-induced SCCs 
were harvested from metastatic tumors and premalignant tumors at the same time when the 
mice were sacrificed. Although this sampling method still enabled analyzing tumors at 
different malignant stages and associating the primary SCC samples with metastatic samples, 
associations of the premalignant samples could not be determined because their origins are 
different from those of the SCC samples. Therefore, these previous studies could not 
eliminate the influence of inter-tumor heterogeneity and could not follow the tumorigenesis 
process of the same tumor over time. In addition, these previous studies performed 
whole-exome sequencing and obtained approximately 50× mean coverage sequencing data, 
whereas Shin et al. (Shin et al., 2017) indicated that approximately 100× sequencing 
coverage is required to detect mutations possessed by ~10% of cells in a tumor from clinical 
samples. Moreover, the known cancer-related gene mutations have been detected with low 
penetrance in tumor samples due to the influence of intra-tumor heterogeneity (Gerlinger et 
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al., 2012; McGranahan et al., 2015) and low tumor content (Shin et al., 2017). Thus, deep 
sequencing coverage is necessary for comprehensive mutation analyses; however, the 
previous data are insufficient to detect low-penetrance variants and to estimate the penetrance 
in a tumor precisely. With regard to these limitations, my approach, involving partial surgery 
and targeted deep sequencing, can contribute to gaining a more comprehensive understanding 
of the tumorigenesis process in different aspects from those obtained in previous research. 
2.2 Results 
2.2.1 Mutational landscape of two tumor series with different fates 
Collaborators established the experimental carcinogenesis model using 35 mice for sample 
collection. One of the main features of the chemical induction mouse skin cancer model is 
that a large number of benign tumors are formed in the early term, only a few tumors 
ultimately become malignant (Schwarz, Münzel and Braeuning, 2013). The collaborators 
previously reported that DMBA-TPA carcinogenesis induction forms approximately 30 
papillomas on the back skin of each mouse (Okumura et al., 2012). In the present study, they 
selected 5–10 DMBA-induced papillomas for each mouse to follow the progression over time. 
The size and the position of each papilloma was recorded during the carcinogenesis 
experiment, and a part of the papilloma lesion was surgically collected to monitor the 
progress of the same tumor over time. This partial tumor sampling was performed from the 
early stage of tumor formation at the ninth week after starting the carcinogenesis experiment. 
By the time all of the mice were sacrificed, a total of 113 tumors were collected at multiple 
time points: 8 (7.1%) tumors became malignant, 68 (60.2%) tumors were still benign, and the 
other 37 (32.7%) tumors had eventually regressed. To understand the differences between the 
tumors that eventually metastasized and those that eventually regressed, I performed a 
comparative time-series analysis for two prospectively sampled tumor series obtained from 
the same mouse: one was sampled at four time points and had eventually metastasized 
(hereafter “malignant series”), and the other was sampled at two time points and eventually 
regressed (hereafter “regressed series”). Conceptual figure of tumor samples is shown in Fig. 
2.1a (Supplementary Fig. S2.1 for photographic images). For simplicity, each sample was 
named as described in the respective images shown in Fig. 2.1a. The collaborators collected 
axillary lymph node metastases as metastatic tumor samples, and a matched tail sample was 
used as a control tissue. 
 For the sensitive detection of mutant alleles from the heterogeneous tumor samples and for 
accurate estimation of the penetrance of each mutation in the tumors, a capture sequencing 
approach was adopted, which can achieve deep-sequencing coverage for targeted genes (see 
Supplementary Table S2.1 for the list of the targeted genes and see Table 2.1 for sequencing 
statistics). The single-nucleotide variants (SNVs) were detected using three variant callers 
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and then filtered according to several criteria to minimize false positives. I defined candidate 
mutation positions as the positions at which SNVs were detected in at least one tumor sample, 
and I focused on the 83 candidate mutation positions with >50× coverage in all seven 
samples (see Table 2.2 for the sequencing depth of these positions). Next, the variant allele 
frequencies (VAFs) were calculated for each of the 83 candidate mutation positions in each 
tumor sample. The VAF is a percentage of variant alleles in the short reads that are mapped to 
a certain genomic position; therefore, it can be considered as an index of the penetrance of a 
mutation in a tumor, and can serve as a clue to infer the intra-tumor heterogeneity and 
sub-clonal structure in tumors (McGranahan et al., 2015; Williams et al., 2016). The VAFs of 
the positions with less than 3 reads supporting the mutation were filtered out (set to 0), and 
were used to estimate the tumor purity for each tumor sample. 
 
Table 2.1. Sequencing statistics for each sample. 
Sample name # clusters # reads # QC %QC %duplicates 
Papi9w 29,494,118 58,988,236 35,567,485 60.30 33.99 
Papi14w 26,126,652 52,253,304 33,379,356 63.88 28.13 
Carc 28,909,899 57,819,798 39,688,768 68.64 23.08 
Meta 31,889,353 63,778,706 36,805,260 57.71 34.39 
Reg9w 40,090,049 80,180,098 51,276,309 63.95 24.28 
Reg14w 31,473,369 62,946,738 32,821,844 52.14 37.64 
Tail (ctrl) 31,218,916 62,437,832 30,439,480 48.75 45.13 
Ave. 31,314,622   59.34 32.38 
The sample names are corresponded to those of Fig. 2.1a. The column #QC (quality control) 
denotes the number of reads that remained after the pre-processing to exclude the low-quality 
sequenced reads. The column %QC denotes the percentage of reads remaining after the 
pre-processing. The column “%duplicates” denotes the percentage of the duplicated reads for 
each sample, which was calculated from the number of filtered reads in the de-duplicate 
process. 
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Table 2.2. Sequencing depth of 83 candidate mutation position for each sample. 
Sample name Max Min Average Median 
Papi9w 976 52 349.76 265 
Papi14w 2152 52 461.87 332 
Carc 1093 72 420.64 319 
Meta 1133 65 438.46 309 
Reg9w 2165 55 543.08 459 
Reg14w 2654 58 527.72 368 
Tail (ctrl) 1236 55 407.33 260 
The statistics of the coverage of the 83 mutation candidate positions for each sample are 
shown. 
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Figure 2.1. Individual mouse of interest and landscape of the mutational status. (a) The 
mouse developed two tumor series: one eventually regressed and the other eventually 
metastasized, designated “regressed series” and “malignant series”, respectively. For 
simplicity, each sample was named as shown near the respective images. (b) The overall 
mutational status of 83 genomic positions for each tumor sample. The bar plot shows the 
number of positions for which mutant alleles were detected. In the tables on the right, each 
column corresponds to a certain position. The upper table shows the heatmap of the VAFs 
with the hierarchical tree color-coded by the mutation groups; “m” denotes that the position 
was detected by the mutation callers as an SNV. The lower table shows the annotation of the 
mutations: the first line indicates whether the mutated position is included in a gene listed in 
the COSMIC: Cancer Gene Census (Futreal et al., 2004), and the second line indicates the 
gene name, including the mutated position and the effect of the mutation. 
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The heterozygous Q61L Hras mutation (chr7:141192550) is known as an initiator of the 
DMBA-TPA experimental carcinogenesis protocol I employed (Brown, Buchmann and 
Balmain, 1990; McCreery et al., 2015; Nassar et al., 2015); therefore, the tumor purity was 
estimated based on the VAF of the Hras mutation (Table 2.3). Correspondingly, the raw VAFs 
were normalized to the estimated tumor purities for proper estimation of the penetrance of the 
mutations in the tumors while excluding the influence of the normal cell-derived reads. 
Finally, the candidate mutation positions with a normalized VAF ≠ 0 were presumed to be the 
mutated positions for each tumor sample. 
 
Table 2.3. Tumor purities and normalization factors. 
Sample 
name 
# Mapped 
reads 
# Variant
 reads 
Raw VAF (%) 95% confidence 
interval (%) 
Tumor purity (%) NF 
Papi9w 912 342 37.500 34.35 – 40.73 68.70 – 81.47 1.3333 
Papi14w 2152 974 45.260 43.14 – 47.39 86.28 – 94.78 1.1047 
Carc 910 277 30.440 27.46 – 33.54 54.92 – 67.09 1.6426 
Meta 836 62 7.4163 5.733 – 9.411 11.47 – 18.81 6.7419 
Reg9w 1271 648 50.983 48.20 – 53.77 96.39 – 100.0 0.9807 
Reg14w 1553 522 33.612 31.26 – 36.02 62.53 – 72.05 1.4875 
The number of mapped reads on the Q61L Hras mutation position (chr7:141192550), the 
number of variant reads which support the Hras mutation, the raw VAF of the Hras mutation, 
the 95% confidence interval of the VAF, estimated tumor purity, and normalization factor 
(NF) for each tumor sample are shown in this table. The heterozygous Hras mutation is an 
initiator of the experimental carcinogenesis protocol we used; therefore, the VAF of the Hras 
mutation should be 50%. Then, I calculated the normalization factor by 0.5 / (raw VAF). I 
used up to the seventh decimal place of the NFs to minimize the effect of rounding errors 
when I calculated the normalized VAFs. 
 
Figure 2.1b shows the overall mutational status for the 83 candidate mutation positions in 
each tumor: the annotation of mutations, heatmap of the normalized VAFs with the 
hierarchical tree, and number of mutated positions are shown (see Supplementary Table S2.2 
for more details). First, the number of mutated positions tended to increase during the benign 
stages in both tumor series; but decreased during the malignant stages. This indicates that the 
cells in the tumor acquired new mutations during the benign state, whereas the cells with 
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several private mutations could not survive after malignancy, suggesting a selective process 
of malignant alteration. 
 Next, I evaluated the commonality of the mutations detected between the tumor types to 
better understand the nature of the inter-tumor heterogeneity. From the heatmap with a 
hierarchical tree shown in Fig. 2.1b, 9/83 (10.84%) mutations were observed in all tumor 
samples, and the other 74/83 (89.16%) mutations were privately observed or sparsely shared 
among tumors. There were mutation groups inherited in each tumor series; in particular, two 
mutation groups were mutually exclusively detected in each tumor series (groups A and B): 
the mutations belonging to group A were observed after 14 weeks in the malignant tumor 
series, whereas the mutations belonging to group B were observed only in the regressed 
tumor series. These mutation groups might reflect the sub-clonal structure in the tumors. 
Specifically, an intronic mutation of Cyld and a nonsense mutation of Ptprc were included in 
mutation group A. The Cyld gene is known as a deubiquitinase whose deubiquitination 
activity negatively regulates the NF-κB pathway and suppresses epidermal tumor progression 
(Kovalenko et al., 2003; Alameda et al., 2010). In addition, Ptprc encodes CD45, which 
regulates the phosphorylation of SRC and JAK family members (Porcu et al., 2012), and 
nonsense mutations in this gene have been recurrently reported in human epithelial and blood 
cancers (http://cancer.sanger.ac.uk/cosmic). Moreover, both of these genes are listed in the 
COSMIC: Cancer Gene Census (CGC) (Futreal et al., 2004), a catalogue of cancer-related 
genes. These two genes showed a high penetrance rate in the tumor samples of the malignant 
tumor series at the later stages (Fig. 2.1b), suggesting that inactivation of these genes caused 
by mutations could have driven the progression of tumor.  
 Moreover, a synonymous mutation in Mll2 and a missense mutation in Trp53 were included 
in mutation group B. Mutations of these genes have been reported to promote cancer 
progression (Futreal et al., 2004), especially the mutation of the Trp53 tumor suppressor gene, 
which has been widely reported as a driver mutation in several cancer types (Kandoth et al., 
2013; Vogelstein et al., 2013). Trp53 is a well-known tumor suppresser gene that plays an 
important role for DNA repair function, cell cycle arrest, and apoptosis (Page et al., 2016). 
Mll2 is a histone methyltransferase and its mutants provoke the genomic instability in tumors 
(Kantidakis et al., 2016). There are reports that the Trp53 mutations induce not only 
abnormal proliferation in tumors but also anti-tumor effects (Einspahr et al., 1999; Page et al., 
2016), and these reports had also discussed the influence of the Trp53-independent apoptosis. 
Therefore, I considered the possibility that these mutations, in Trp53 and Mll2 genes, which 
are related to genomic instability, could have induced the Trp53-independent apoptosis, 
which in turn resulting in the eventual regression of the tumor. 
 Another mutation group, group C, showed an opposite pattern to that of the other two tumor 
series. The tumor of the malignant series acquired group C mutations when it was benign, but 
did not inherit these mutations after malignant transformation. By contrast, the tumor of the 
regressed series acquired the mutations at a later stage of the benign term. The mutations of 
genes listed in the CGC as cancer-related genes, although in non-exonic regions, were 
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enriched in group C. For instance, downstream mutation of Mtor and intronic mutations of 
Nf1 and Jak1 were included in the group C, and these genes have a crosstalk and/or direct 
regulatory relationship with the RAS signaling pathway (Bollag et al., 1996; Rawlings, 
Rosler and Harrison, 2004; Laplante and Sabatini, 2013). In comparison, group D is a 
mutation group that was observed only in the early stages of the malignant tumor series, and 
there are no gene mutations listed in the CGC. This suggests that the peripheral genomic 
region of cancer-related genes was more actively mutated in the regressed tumor series. 
Furthermore, focusing on the malignant tumor series, the mutations showing relatively high 
VAFs in the 9th week papilloma group (group D) were not detected at the later stages, and the 
mutations conserved after the 14th week of papilloma development (group A) were not 
detected in the 9th week; hence, it appears that the 9th to 14th week represents a period of 
substantial changes in the intra-tumor sub-clonal structure for malignant alteration. Thus, the 
mutational status among tumors suggests that the sub-clonal structure in the tumors 
continuously changes over time and also differs between tumors with different fates. 
 Furthermore, to evaluate the adequacy of these results, I reviewed previous studies using the 
same mouse carcinogenesis protocol. Nassar et al. (Nassar et al., 2015) and McCreery et al. 
(McCreery et al., 2015) performed large-scale analyses of SCC induced in the skin of mice 
with DMBA-TPA, and identified recurrent mutations among the SCCs, including exclusive 
driver mutations of the RAS family, and revealed the mutational signature of DMBA 
enriched with A>T base substitutions. In my results, all of the tumors had the Q61L Hras 
mutation, which was reported as the initial driver mutation for this model (Brown, Buchmann 
and Balmain, 1990; McCreery et al., 2015; Nassar et al., 2015), and the substitution pattern 
of the 83 candidate mutation positions showed enrichment for the A>T base substitution (Fig. 
2.2); therefore, my results are consistent with previous studies of this model. 
 
Figure 2.2. Substitution 
patterns of SNVs. The 
detected SNVs were 
categorized by the 
substitution patterns. The 
bar-plot denotes the 
count of each 
substitution pattern for 
each tumor sample. 
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Of note, the previous studies identified a recurrent mutation in the Trp53 gene in the 
malignant SCCs, whereas this mutation was only detected in the early stage of the regressed 
tumor series in the present study. This indicates that the single Trp53 mutation does not 
promote tumor progression. By contrast, the stop-gain mutation of Ptprc, which belongs to 
the protein tyrosine phosphatase (PTP) family, was inherited in the malignant tumor series. 
Nassar et al. (Nassar et al., 2015) also identified another gene belonging to the PTP family, 
Ptprm, that showed recurrent mutation; hence, the PTP family appears to play a key role in 
the DMBA-TPA experimental carcinogenesis system. 
 The results highlighted thus far exhibited an increase in the number of mutations while the 
tumor is in the benign stage and later a decrease after malignant alteration. The tumor series 
with different fates, i.e., becoming malignant and eventually regressing, acquired and 
inherited different mutations; however, not all mutations were inherited, and the VAFs also 
changed over time. These results suggest that selection pressure was applied to induce the 
process of malignant alteration, and the sub-clonal structure not only differs between tumor 
fates but also changes over time. 
2.2.2 Degree of shared mutations between tumors within and among tumor
 series 
Subsequently, I evaluated the similarity (or dissimilarity) between tumors by applying the 
Jaccard similarity coefficient and the generalized Jaccard similarity coefficient (Fig. 2.3). For 
this analysis, I assumed the positions with a VAF ≠ 0 of the 83 candidate mutation positions 
were mutated, and defined a set of mutations for each tumor sample. To determine the 
commonality of the mutated positions between tumors, I calculated the Jaccard similarity 
coefficient between the sets of mutations. The heatmap of the Jaccard similarity coefficient 
(Fig. 2.3a) indicated that the similarity between tumors within the same tumor series was 
higher than that between tumor series; however, the similarity between the 9th week and later 
papilloma samples of the malignant tumor series was only moderate. This result supports that 
different mutations are inherited in each tumor series, and confirms that the intra-tumor 
structure existing in the malignant tumor series dramatically changed between the 9th to 14th 
weeks, as proposed from the results of the mutational status analysis (Fig. 2.1b). 
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Figure 2.3. Heatmap of similarity between tumors. (a) Heatmap of the Jaccard similarity 
coefficient between tumor samples. (b) Heatmap of the generalized Jaccard similarity 
coefficient between tumor samples. 
Moreover, I applied the generalized Jaccard similarity coefficient to quantitatively evaluate 
the inheritance of the mutations. I used the normalized VAF value to represent the penetrance 
of a mutation in a tumor, and defined a numeric vector constructed by the normalized VAFs 
of the 83 candidate mutation positions for each tumor sample. The generalized Jaccard 
similarity coefficient between these numeric vectors then corresponds to the commonality of 
the abundances of the mutations between tumors. The heatmap of the generalized Jaccard 
similarity coefficient between tumors (Fig. 2.3b) not only accentuates the same features 
represented in Fig. 2.3a but also indicates that the penetrance of the mutations was more 
highly conserved between tumors of the regressed tumor series than that between tumors of 
the malignant tumor series. Consistently, the scatter plot of the normalized VAFs between 
tumors (Fig. 2.4) showed that the plots between tumors with relatively low generalized 
Jaccard similarity coefficients were clearly biased toward both axes, whereas the plots 
between tumors with higher similarity coefficients, especially those between tumors within 
the regressed tumor series, basically lay on the diagonal line. These results suggest that 
tumors of the regressed series were relatively stable over time, whereas the intra-tumor 
structure of the malignant tumor series was crucially changed between the 9th to 14th weeks, 
and then continuously changed gradually after the 14th week. 
 
 22 
 
  
Figure 2.4. Scatter-plot of VAFs of 83 candidate mutation positions. VAFs of the 83 
candidate positions were plotted. Each dot corresponds to a certain genomic position so that 
83 plots are drawn in each of the boxes. If the VAFs of a certain position was same value 
between tumors, the corresponded dot should be on the diagonal line. 
 
2.2.3 Intra-tumor heterogeneity and evolutionary process within tumors 
Next, I focused on the intra-tumor heterogeneity. To evaluate the degree of intra-tumor 
heterogeneity, I applied an entropy parameter for the normalized VAFs of the 83 candidate 
mutation positions. Entropy is often used as an index of the complexity or information 
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content of certain events. Dr. Shannon proposed an expected value of the information amount 
as “information entropy” (Shannon, 1948), and this concept has been widely applied in the 
fields of informatics, statistics, and biology (Newton et al., 2014). In the present study, I 
regarded the intra-tumor heterogeneity to reflect the complexity of the tumor, which was 
evaluated by the sum of the complexity calculated for each mutation. 
 As shown in Fig. 2.5, the spectrum of the normalized VAFs demonstrated that all 
normalized VAFs were below the 50% line (the plot on the 50% line in each of the tumor 
samples corresponds to the Hras mutation). The genomic positions with a normalized VAF of 
0% indicates that the position is homozygous to that of the reference base in all tumor cells, 
while the positions with a normalized VAF of 50% indicates that the position is heterozygous 
in all tumor cells; in other words, these positions are homogeneous among tumor cells. Based 
on this result, I assumed that there was no copy number variation (CNV) at the 83 candidate 
mutation positions and that these mutations occurred on one side of the diploids. Moreover, 
the clonal structure of a tumor can be represented by a combination of mutations; therefore, I 
assumed that the mutations are independent but do not contradict each other. With these 
assumptions, I defined an entropy parameter as the degree of complexity of a tumor (see 
Materials and Methods for more details), which was calculated from the normalized VAFs of 
the heterogeneous positions for each tumor sample (Fig. 2.5, bottom). As a result, the entropy 
was found to be maximal in the 14th week papilloma sample, and then decreased after 
becoming malignant in the malignant tumor series. Moreover, the entropy value of the 
regressed tumor series decreased over time, and was lower than that of the 14th week 
papilloma sample of the malignant tumor series. These results suggest that the tumors of the 
malignant series gradually acquired intra-tumor heterogeneity before developing malignancy, 
whereas the tumors of the regressed series could not sustain the heterogeneous characteristic. 
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Figure 2.5. Spectrum of 
normalized VAFs and 
entropy of each tumor 
sample. The chart shows 
the spectrum of the 
normalized VAFs, where 
each column represents a 
certain sample, and the 
y-axis corresponds to the 
normalized VAF. Each 
dot corresponds to a 
certain candidate 
mutation position for a 
total of 83 dots plotted 
for each column. The 
values shown at the 
bottom of each column 
denote the entropy 
parameter values. 
 
Furthermore, I estimated the mutation rate to obtain insight into the process of sub-clonal 
evolution in the tumors. Under the assumption that mutations are neutrally accumulated and 
penetrate a tumor over time, the number of mutations should proportionally increase with 
time and the mutation rate of a tumor cell should be constant. Williams et al. (Williams et al., 
2016) proposed a regression analysis method to estimate the mutation rate from VAFs. 
According to their results, I assumed that the position with a normalized VAF of 25% or less 
in the 83 candidate mutation positions represented a sub-clonal mutation. For each tumor 
sample, the sub-clonal mutations were sorted in ascending order according to the inverse of 
the normalized VAFs, and the normalized VAFs were plotted against these sorted ranks, 
which were used to perform the regression analysis respectively for the ranks (Fig. 2.6). The 
slope of the regression line denotes the estimated apparent mutation rate (shown at the right 
bottom of each plot), and the coefficient of determination (R2) denotes the neutrality of the 
mutations (shown at the left top of each plot). When R2 ≥ 0.98, the tumor was considered to 
have acquired mutations neutrally; otherwise, the tumor was considered to have acquired 
mutations in a non-neutral manner (i.e., selectively). First, the mutation rates of the benign 
tumors were lower than those of the tumors that transitioned to a malignant status; this effect 
was particularly notable in the 9th week early-stage papilloma sample of the regressed tumor 
series. For the malignant tumor series (Fig. 2.6a–d), the mutations were neutrally acquired 
 25 
 
until the 9th week papilloma, but were then acquired in a biased manner after the 9th week 
papilloma; notably, an early selection mode (Williams et al., 2016) was suggested for 
carcinoma and metastasis progression, indicating that the tumor had already gained dominant 
(selected) mutations (sub-clones) before transitioning to carcinoma. In brief, the tumor was 
exposed to the selection pressure after 9 weeks before becoming malignant. According to the 
mutational landscape (Fig. 2.1b) and the similarity between tumors (Fig. 2.3), the intra-tumor 
structure of the malignant tumor series was dramatically changed between the 9th and 14th 
weeks, and then was comparatively conserved thereafter. Thus, the selection pressure that had 
been in effect from the 9th to 14th weeks might have caused the dramatic changes in the tumor. 
By contrast, for the regressed tumor-series (Fig. 2.6e–f), the tumor had already been 
acquiring the mutations selectively before the 9th week; however, the process of mutation 
acquisition after the 9th week was comparatively neutral. These results suggest that different 
tumor series undergo distinct evolutionary processes, indicating that the tumor fate is 
determined from a quite early stage. 
 
Figure 2.6. Mutation rate analysis for the malignant tumor series (a–d) and the regressed 
tumor series (e, f). The x-axis corresponds to the inverse allele frequency and the y-axis 
corresponds to the cumulative number of mutations. The apparent mutation rate is shown at 
the right bottom of each plot, and the coefficient of determination (R2) is shown at the left top 
of each plot. 
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2.3 Discussion 
In this study, I compared tumor series with different fates through analysis of a DMBA-TPA 
carcinogenesis protocol. Although the DMBA-TPA protocol is limited to the analysis of the 
tumors initiated by RAS family mutation, it is widely accepted that the mutation landscape, 
mutation burden, and gene expression profile of the SCCs formed on the mouse back skin 
through the DMBA-TPA protocol are largely similar to human SCCs such as head and neck, 
esophageal, lung, and cervical SCCs (Ginos et al., 2004; Huang and Balmain, 2014; 
McCreery et al., 2015; Nassar et al., 2015; Aoto et al., 2017). In line with these previous 
studies, my results indicated that although the carcinogenesis protocol using DMBA-TPA 
provides information on the initial driver mutations and promotes the formation of a number 
of papillomas on the mouse skin, further drivers are clearly required for the malignant 
alteration. In most cases, papillomas could not become carcinomas, meaning that further 
driver events did not occur, while also confirming the general difficulty of malignant 
transformation. I further presumed that there are differences in the genomic mutations and in 
the sub-clonal structure among tumors with different fates. To understand the difference 
between the eventually metastasized and regressed tumors, I performed targeted deep 
sequencing for these two tumor-series of different destinies sampled from the same mouse. 
This comparative analysis provided an opportunity to understand the factors and timing of the 
tumor fate determination. 
Previous cancer studies reported that each tumor has a different mutational status and 
multiple driver mutations are accumulated during tumor progression (Futreal et al., 2004; 
Vogelstein et al., 2013; Martincorena and Campbell, 2015; Tomczak, Czerwińska and 
Wiznerowicz, 2015). To understand the evolutionary process of tumors, the temporal changes 
of the mutational trend, e.g., the order of the occurrence of driver events, have also been 
discussed (Fearon and Vogelstein, 1990; Vogelstein et al., 2013; McGranahan and Swanton, 
2015, 2017; McGranahan et al., 2015; Shain et al., 2015; Jamal-Hanjani et al., 2017). These 
studies identified that known driver mutations were significantly biased to be clonal; hence, it 
has been considered that these driver mutations are acquired before malignant transformation, 
and the highly malignant sub-clones with these driver mutations originate to form malignant 
tumors (Greaves and Maley, 2012; Martincorena and Campbell, 2015). Consistent with these 
previous hypotheses, my results suggest that tumors with different fates acquired different 
mutations, accompanied by changes in the intra-tumor structure over time, and also suggest 
that selection pressure could have influenced the benign tumors to select highly malignant 
sub-clones in the tumors.  
Moreover, my results provide new insight into the timing of the selective event and fate 
determination of tumors. The selection event for malignant alteration might have occurred 
between the 9th and 14th weeks, corresponding to the transformation from early-stage 
papilloma to late-stage papilloma, and the evolutionary process of these two tumor-series 
 27 
 
differed at the time of the 9th week early-stage papilloma. Furthermore, only the tumors that 
could obtain and sustain sufficient intra-tumor heterogeneity could become malignant. The 
majority of cancer studies conducted to date have focused on malignant tumors (Tomczak, 
Czerwińska and Wiznerowicz, 2015). Although several studies analyzed tumors at both the 
benign and malignant stages, these tumor types are typically collected from different patients 
(Jamal-Hanjani et al., 2017), or the adjacent lesions of primary tumors were collected as 
precursor lesions (Shain et al., 2015); therefore, these studies could not follow the temporal 
changes of the same tumors respectively. Thus, my prospective approach is complementary to 
existing cancer studies, and offers novel insights. 
Adoption of this prospective study model can provide new opportunities for gaining a 
detailed understanding of the evolutionary process of tumors by conducting statistical 
analysis with increased numbers of mice and tumor series, and also by analyzing the whole 
genome rather than targeted regions. Moreover, my study can also be relevant to improving 
surgical treatment resistance and prognostic prediction (Ludwig and Weinstein, 2005). In 
particular, my results and further statistical analysis with more mice can help to identify 
factors that determine the fate of tumors and the prognostic biomarkers for guiding a more 
precise treatment strategy. However, the gene signatures and the timeline of tumor 
progression might vary in different tumor samples; therefore, further experiments are 
required to verify these aspects. As part of my future works, I am planning to perform 
whole-exome sequencing for more tumor series, and other omics analyses such as 
transcriptomics and epigenomics. 
2.4 Materials and Methods 
2.4.1 Mice 
This study was conducted in strict accordance with the recommendations in the Guide for the 
Care and Use of Laboratory Animals of the Ministry of Education, Culture, Sports, Science, 
and Technology of Japan. The protocol was approved by the Committee on the Ethics of 
Animal Experiments of Chiba Cancer Center (Permit Number: 17-14). All efforts were made 
to minimize suffering. FVB/N mice were purchased from CLEA Japan (Tokyo, Japan). 
2.4.2 Skin carcinogenesis and tumor sampling 
DMBA was used as the carcinogen and TPA was used as a promoter to induce SCC on the 
back of the mouse skin. Collaborators treated 35 FVB/N mice according to a two-stage 
carcinogenesis protocol. At 8 weeks of age, the female mice were carefully shaved with an 
electric clipper, and two days after shaving, a single dose of DMBA (25 µg/mouse in 200 µL 
of acetone) was applied to the shaved dorsal back skin. One week after initiation, tumor 
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growth was promoted with TPA (10 µg/mouse in 200 µL of acetone) twice weekly for 20 
weeks. For each mouse, 5–10 papillomas were selected to follow tumor progression over 
time. The number, size (diameter in mm), and position of each papilloma were recorded as of 
9, 14, and 23 weeks, and carcinoma development was monitored for up to 33 weeks post-TPA 
treatment. To obtain the prospective tumor samples from the same tumor, a part 
(approximately half) of the papilloma lesions was surgically collected so that the remaining 
part could grow toward the later stages. These collected samples were further cut in half; 
therefore, one quarter of each tumor was used for this research, and the remaining quarter 
was preserved for subsequent research. Collaborators determined benign tumors (papillomas) 
and malignant tumors (carcinomas) by visual inspection. Papillomas appear as outgrowths on 
the mouse back skin. Some of them become flattened on the skin with malignant 
transformation involving penetration of the deep dermis. In general, these tumors can be 
easily distinguishable from one another (Okumura et al., 2012; Huang and Balmain, 2014), 
and I did not use any of the tumors that could not be clearly classified as papilloma or 
carcinoma, such as an intermediate type. The mice were sacrificed by cervical dislocation 
when carcinoma formed and axillary lymph node metastases were visually confirmed, or 
when the tumor volume reached 10% of the mouse body weight. They collected axillary 
lymph node metastases as metastatic tumor samples. As a control tissue, they collected a tail 
sample from each mouse before starting the DMBA-TPA experiment. Finally, the time-series 
tumor samples that eventually became malignant and those that regressed were obtained from 
the same mouse (Fig. 2.1a and Supplementary Fig. S2.1). 
2.4.3 Sample preparation and targeted deep sequencing 
For sensitive detection of the low-frequent mutant alleles and for precise estimation of the 
VAFs, I adopted a targeted capture-based deep-sequencing approach. I and collaborators 
compiled a list of the target genes by reference to the COSMIC database 
(http://cancer.sanger.ac.uk) (Forbes et al., 2017) to select the most frequently mutated genes 
in the SCC samples, and used previous reports of the housekeeping genes (Eisenberg and 
Levanon, 2003; Vilella et al., 2009) to select the genes deemed to be most crucial for cell 
survival. Finally, we selected 500 genes and designed the target capture bait library using the 
Agilent SureDesign program (https://earray.chem.agilent.com/suredesign; see Supplementary 
Table S2.1 for details). 
 For sample preparation, the genomic DNA was extracted from the tumors and normal 
tissues (tail of each mouse) using DNAiso Reagent (9770A; Takara, Otsu, Japan). The 
extracts were treated according to the SureSelectXT Target Enrichment System for Illumina 
Paired-End Sequencing Protocol for 200-ng samples (Agilent Technology, Santa Clara, CA, 
USA). In this step, pre-capture polymerase chain reaction (PCR) was performed for 10 cycles, 
the incubation for library hybridization was performed for 24 h, and post-capture PCR was 
performed for 12 cycles. The products were confirmed using the Agilent 2100 bioanalyzer. 
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The paired-end sequencing (2 × 75 bp) was performed using Illumina MiSeq System with 
MiSeq Reagent Kit v3 (150 cycle; Illumina, San Diego, CA, USA). 
2.4.4 Sequence data analysis 
The sequencing adapters and low-quality ends of raw sequenced reads were trimmed using 
Trimmomatic (version-0.36) (Bolger, Lohse and Usadel, 2014) with the options 
“ILLUMINACLIP:${adapter.fa}:2:30:10 LEADING:30 TRAILING:30 
SLIDINGWINDOW:4:25 MINLEN:1”, and the low-quality reads were filtered using 
FASTX-Toolkit (http://hannonlab.cshl.edu/fastx_toolkit/index.html) with the options “-q 30 
and -p 80”. Next, the remaining paired reads were mapped to the mouse reference genome 
(GRCm38-release71.fa) using the BWA-MEM algorithm (Li and Durbin, 2009) 
(Burrows-Wheeler Aligner; BWA; version-0.7.15-r1140). The reads with a mapping quality 
under 25 were filtered, and the others were treated according to the Genome Analysis Toolkit 
(GATK) best practices (de-duplicates, base recalibration, and local realignment) using GATK 
(McKenna et al., 2010) (version 3.6), picard tools (http://broadinstitute.github.io/picard; 
version 2.6.0), and samtools (Li et al., 2009) (version 1.3.1). The SNVs were detected by 
MuTect2 (Cibulskis et al., 2013) (within GATK 3.6; default settings), Strelka (Saunders et al., 
2012) (version 1.0.14; skip depth filters to follow the recommendation), and LoFreq (Wilm et 
al., 2012) (version 2.1.2; default settings with 0.01 significance level and Bonferroni 
correction). Among these unions of detected SNVs, the SNVs corresponding to any of the 
following cases were excluded: (a) registered in the dbSNP (Sherry, 2001) (release version 3), 
(b) supported by <3 reads, (c) reads supporting mutant alleles mapped in the control sample, 
and (d) other SNVs detected within 10 bp on either side. I defined candidate mutation 
positions as the positions detected to be SNVs in at least one tumor sample, which clearly 
passed above the filters, and I focused on 83 candidate mutation positions whose sequence 
coverage was >50× in all 7 samples. Next, I calculated the percentage of variant alleles 
among the mapped short reads for each candidate mutation position from the mapped read 
bases whose Phred quality score was >13. The VAFs of the positions for which the number of 
reads supporting the mutation was less than 3 were filtered out (set to 0). Moreover, I 
estimated the tumor purity of the tumor samples according to the VAF of the Q61L Hras 
mutation (chr7:141192550), because this heterozygous mutation is known as an initiator of 
DMBA-TPA experimental carcinogenesis (Brown, Buchmann and Balmain, 1990; McCreery 
et al., 2015; Nassar et al., 2015). Accordingly, I estimated the proper penetrance rates of the 
mutations in the tumors while excluding the influence of the normal cell-derived reads by 
normalizing the raw VAFs with the estimated tumor purities. The normalized VAFs were used 
for the subsequent analyses. The sequencing, read mapping, and tumor purities are 
summarized in Tables 2.1–2.3. 
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2.4.5 Hierarchical clustering of candidate mutation positions 
I assigned a 6-dimensional vector constructed by the normalized VAFs of 6 tumor samples 
for each of the 83 candidate mutation positions, and performed agglomerative hierarchical 
clustering. I adopted a weighted Manhattan distance (Canberra distance) approach as the 
distance measure between the assigned numeric vectors and used the group mean method for 
clustering. The Canberra distance between numeric vectors x and y can be calculated as 
follows: 
!(#, %) = ( |*+ − -+||*+| + |-+|+ 			 (2.1). 
2.4.6 Similarity measurements between tumors 
To evaluate the similarity between tumors, I applied the Jaccard similarity coefficient and 
generalized Jaccard similarity coefficient. The Jaccard similarity coefficient is a similarity 
measure representing the degree of commonality between two sets. The Jaccard similarity 
coefficient between sets A and B can be calculated as follows: 
3(4, 5) = |4 ∩ 5||4 ∪ 5|			(2.2). 
In my study, I defined a set of mutations for each tumor sample and calculated the Jaccard 
similarity coefficient between the sets of mutations to represent the degree of similarity 
between tumors (Makohon-Moore et al., 2017). 
 In addition, I defined an 83-dimensional numeric vector constructed by the VAFs of the 83 
candidate mutation positions, and assigned a numeric vector for each tumor sample. I 
calculated the generalized Jaccard similarity coefficient between tumor samples using the 
defined numeric vectors as the similarity between the tumors. The generalized Jaccard 
similarity coefficient between numeric vectors x and y can be calculated as follows: 
83(#, %) = ∑ min(*+, -+)+∑ max(*+, -+)+ 			(2.3). 
2.4.7 Evaluation of intra-tumor heterogeneity 
To evaluate the intra-tumor heterogeneity, I applied an entropy parameter. I regarded the 
intra-tumor heterogeneity as the complexity of the tumor, which was evaluated by the sum of 
the complexity provided by each mutation. From the spectrum of the normalized VAFs (Fig. 
3), I assumed that there was no CNV at the 83 candidate mutation positions and that these 
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mutations occurred on one side of the diploids. With this assumption, I defined the 
probability that a cell randomly selected from a tumor i has a mutation m as P(2 × nVAFm,i), 
and defined its self-information amount as -logP(2×nVAFm,i), where nVAFm,i denotes a 
normalized VAF of a mutation m in a tumor Ti. Moreover, the clonal structure of a tumor can 
be represented by a combination of mutations; thus, I assumed that the mutations are 
independent but do not contradict each other. Under these assumptions, I defined an entropy 
parameter as the degree of the complexity of a tumor according to the following equation: 
@(A+) = − ( logEF2 × nVAFK,+LK∈NO 			(2.4), 
where Mi denotes a set of candidate mutations in a tumor Ti. 
2.4.8 Estimation of the mutation rate and evolutionary process 
According to a previously reported method (Williams et al., 2016), the mutation rate and 
evolutionary process of the tumors were estimated from the normalized VAFs. On the 
assumption that the sub-clonal mutations were neutrally accumulated and penetrated a tumor 
over time, the number of mutations should proportionally increase with time, and thus the 
mutation rate of a given tumor should be constant. Therefore, Williams et al. (Williams et al., 
2016) proposed a fitting model to estimate the mutation rate of a tumor and to infer the 
neutrality of the sub-clonal mutations in a tumor as follows: 
Q(R) = ST U1R − 1RKVWX				(2.5), 
where f denotes the relative fraction of a mutation in a tumor, M(f) denotes the cumulative 
number of mutations, and µe denotes the apparent mutation rate. The f value corresponds to 
the VAF of a mutation, and fmax = 0.5 when assuming a diploid tumor. Under the same 
assumptions described above, the VAF of a mutation should increase for mutations that occur 
earlier; hence, the cumulative number of mutations M(f) can be estimated by sorting the 
mutations according to the VAFs. Thus, I assumed that the position with a normalized VAF 
that was less than 25% in the 83 candidate mutation positions was a sub-clonal mutation. To 
exclude false positives, I eliminated the mutations whose VAFs were below 2% in this 
analysis. For each tumor sample, the sub-clonal mutations were sorted in ascending order by 
the inverse of the normalized VAFs, the normalized VAFs were plotted against these ranks, 
and regression analysis was performed based on equation (2.5). Finally, the slope of the 
regression line and the coefficient of determination were calculated, respectively. 
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2.4.9 Data availability 
All sequencing data used in this work are available from the DNA Data Bank of Japan 
(DDBJ) Sequence Read Archive (DRA) under the accession number DRA007132. 
2.5 Conclusion 
In this chapter, I have described the results of prospective cancer genome analysis for two 
tumor series, with one ending as a metastasized tumor and the other as a regressed tumor. The 
mutational landscape shows that these tumor series had acquired and inherited different 
mutations compared to each other. These results suggested that it is important for malignant 
transformation to increase and maintain intra-tumor heterogeneity. Moreover, selection 
pressure in tumor evolution could affect during the formation of late-stage benign tumors; 
while on the other hand, the tumor fates might be determined at a considerably earlier stage. 
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Chapter 3 
DEclust: A statistical approach for obtaining differential 
expression profiles of multiple conditions 
In this chapter, I propose a novel analytical method for multi-conditional transcriptome data 
to extract gene clusters whose expression patterns are statistically overrepresented among 
multiple conditions. Afterwards, I show the results of cancer transcriptome analysis of 
applying the proposing method to the tumors obtained by the experimental carcinogenesis 
(Aoto et al., 2017). 
 High-throughput RNA sequencing technology is widely used to comprehensively detect and 
quantify cellular gene expression. Thus, numerous analytical methods have been proposed for 
identifying differentially expressed genes (DEGs) between paired samples such as tumor and 
control specimens, but few studies have reported methods for analyzing differential 
expression under multiple conditions. I propose a novel method, DEclust, for differential 
expression analysis among more than two matched samples from distinct tissues or 
conditions. As compared to conventional clustering methods, DEclust more accurately 
extracts statistically significant gene clusters from multi-conditional transcriptome data, 
particularly when replicates of quantitative experiments are available. 
 As a result of applying my method to the cancer transcriptome analysis, DEclust extracted 
16 gene clusters whose expression patterns were discriminative in the process of the tumor 
progression; moreover, the genes which were belonging to each of these clusters were 
significantly enriched for biological functions. 
 DEclust can be used for any multi-conditional transcriptome data, as well as for extending 
any DEG detection tool for paired samples to multiple samples. Accordingly, DEclust can be 
used for a wide range of applications for transcriptome data analysis. DEclust is freely 
available at http://www.dna.bio.keio.ac.jp/software/DEclust. 
3.1 Background 
3.1.1 RNA sequencing and gene expression analysis 
As mentioned in Chapter 1, high-throughput RNA sequencing (RNA-Seq) technology has 
been used to comprehensively detect and quantify cellular gene expression (Wang, Gerstein 
and Snyder, 2009). Most transcriptomic studies, such as those used in cancer research, are 
focused on genes whose expression levels differ in a statistically significant manner between 
experimental conditions, and numerous analytical methods for identifying differentially 
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expressed genes (DEGs) between a pair of matched samples—such as tumor and control 
specimens—based on RNA-Seq data. edgeR (Robinson, McCarthy and Smyth, 2010), 
DESeq2 (Love, Huber and Anders, 2014), and cuffdiff2 (Trapnell et al., 2013) are widely 
used for comprehensively quantifying gene expression levels and detecting DEGs between 
a pair of samples or a pair of experimental conditions by using statistical tests; however, to 
date, few studies have proposed analytical methods for detecting differential expression 
among multiple conditions. 
3.1.2 Cluster analysis 
Cluster analysis according to gene expression patterns is a simple analysis that is performed 
on multi-conditional transcriptome data for predicting gene functions, searching for 
biomarkers, and summarizing large datasets; in cluster analysis, sets of objects are grouped in 
such a manner that objects in the same group (“cluster”) are similar to each other but are 
different from objects in other groups. For clustering based on gene-expression patterns, 
Euclidean distance, Pearson’s correlation, and cosine distance are commonly used for 
measures of distance or similarity between genes (D’haeseleer, 2005). Although the 
conventional definitions of distance appear to be useful (D’haeseleer, 2005), they do not 
consider any statistical significance based on a dispersion of gene expression: Experimentally 
quantified gene expression levels possess dispersion due to stochastic biological noise, 
experimental error, and other factors (Elowitz et al., 2002; Trapnell et al., 2013), but the 
conventional definitions of distance consider only the means of expression levels among 
replicates. Therefore, the existing clustering methods cannot distinguish significant 
differences in gene expression levels from stochastic biological noise, and, consequently, 
these methods cannot accurately generate statistically overrepresented patterns of gene 
expression profiles among multiple conditions from the expression profiles of the genes 
whose expression levels are significantly changed among the experimental conditions. 
 To overcome the aforementioned drawbacks associated with analysis methods, I propose 
here a novel approach for differential expression analysis. My method, termed DEclust, 
provides a scoring system for a hierarchical clustering based on differential expression 
profiles among multiple conditions. I define a collection of statistical test results obtained for 
all combinatorial pairs of conditions as a pairwise differential expression test (DET) profile 
and assign it to each gene. DEclust searches for a set of statistically overrepresented patterns 
on DET profiles among multiple conditions by clustering the pairwise DET profiles. 
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3.2 Results and Discussion 
3.2.1 Algorithm 
For applying a statistical approach to multi-conditional transcriptome data, DEclust adopts a 
novel distance score between a pair of clusters of genes based on their pairwise DET profiles. 
The pairwise DET profile is an integer vector constructed from statistical test results for all 
pairs of conditions. In accordance with common analytical pipelines, RNA-Seq reads are 
mapped to a reference genome, and an expression level for each gene per condition is 
estimated. Based on these expression values, a statistical test is applied to all pairs of 
conditions by using an existing DEG detection tool. The result of the statistical test of 
differential expression for a pair of conditions is labeled as +1 (upregulated pair), −1 
(downregulated pair) or 0 (insignificantly altered pair). Subsequently, these integer values for 
all pairs of conditions are formed in the vector as a pairwise DET profile. Therefore, the 
pairwise DET profile features NC2 dimensions (N is the number of conditions). The 
expression level of a gene g in condition k is denoted as ekg. If the expression level, ekg, is 
statistically different from elg, then an element of the corresponding dimension in the pairwise 
DET profile is defined to be 1 (ekg < elg) or −1 (ekg > elg); otherwise, it is 0 (Fig. 3.1a). The 
pairwise DET profile assigned to a gene g is defined as follows: 
Z(8) = F![,\] , ![,^] ,… , !`a[,`] L			(3.1),	
!b,c] = d +1	Feb] < ec]L																		0			(no − significance)−1	Feb] > ec]L , 
where dk,lg represents the statistical test result for the comparison between a pair of certain 
conditions k and l. 
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Figure 3.1. Pairwise DET profile and definition of gain and loss. (a) An example of a 
pairwise DET profile for genes. All pairwise combinations of four conditions (A, B, C, and 
D) constitute the six-dimensional pairwise DET profile. (b) An example of the calculation of 
gains and losses. The pairwise DET profile of Cluster 1 is (0 1 0 0 0 0), and the pairwise DET 
profile of Cluster 2 is (0 1 0 1 0 0); thus, the pairwise DET profile v(C1C2) is (0 1 0 0 0 0 0). 
Accordingly, the number of elements that are 1 or -1 in v(C1C2) is 1 (s = 1), and that in |C1
C2| is 4; therefore, gain1,2 = 4. The total number of elements that are 1 or −1 in v{gCn
Cm} is 7 (t = 7). Hence, loss1,2 = 3 and D(C1, C2) = 0.857. 
 
For inducing statistically overrepresented patterns on DET profiles among multiple 
conditions, inter-cluster distance is defined to be shorter when a large number of the same 
statistical test results are shared between the given clusters of genes. DEclust calculates the 
rate of the statistical test results shared among pairwise DET profiles of genes in the clusters 
to be merged. First, the definition of the pairwise DET profile is extended to a set (cluster) of 
genes as follows. An element that corresponds to a statistical test result between a pair of 
conditions k and l in the pairwise DET profile for a cluster Cn of genes is defined to be 1 if 
dk,lg = 1 for gCn and −1 if dk,lg = −1 for gCn; otherwise, it is 0. Thus, the pairwise 
DET profile assigned for a cluster Cn is defined as follows: 
Z(mn) = F![,\op , ![,^op ,… , !|o|a[,|o|op L			(3.2) 
Second, the distance between two clusters Cn and Cm based on the pairwise DET profile is 
defined as follows: 
q(mn, mK) = 1 − Fgainn,K − lossn,KLFgainn,K + lossn,KL			(3.3), 
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where gainn,m is defined as s × |CnCm|, for s denoting the number of elements of +1 or −1 in 
the pairwise DET profile v(CnCm) for the union of the clusters Cn and Cm; and lossn,m is 
defined to be (t – gainn,m), for t denoting the total number of elements of +1 or −1 in the 
pairwise DET profiles	v(g) for all genes g in the union of the clusters Cn and Cm. 
 Fig. 3.1b shows an example of the gain and loss; the gain and loss are non-negative integer 
values and if gainn,m = 0 and lossn,m = 0, then D(Cn, Cm) = 0. If all pairwise DET profiles of 
genes in a union of clusters are identical, gainn,m = t and lossn,m = 0, and thus D(Cn, Cm) = 0. 
By contrast, if no element has the same value of +1 or −1 among all pairwise DET profiles in 
a union of clusters, gainn,m = 0 and lossn,m = t, and therefore D(Cn, Cm) = 2. Thus, D(Cn, Cm) 
corresponds to an indicator of the shared (or unshared) statistical test result rate in the union 
of the clusters Cn and Cm. If any pairs of clusters have the same distance under the definition 
of equation (3.3), DEclust uses a conventional distance measure to search for the closest pair 
of clusters. 
 By using the aforementioned definition of distance, DEclust adopts the 
agglomerative-hierarchical-type clustering method to identify statistically overrepresented 
patterns on DET profiles among multiple conditions. DEclust initially merges genes that 
feature the same statistical test results (i.e., the same pairwise DET profile), and subsequently 
merges two gene clusters Cn and Cm with minimum distance D(Cn, Cm) so as to conserve the 
common statistical test results as much as possible. In this manner, DEclust can not only be 
applied to multi-conditional transcriptome data but also be used to extract statistically 
significant gene clusters (Algorithm 3.1). 
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Algorithm 3.1. Pseudo code of DEclust. 
 Input: r = {8[, 8\,… , 8n} (set of genes to be clustered). 
 Output: N (Hierarchical tree written in Newick tree format). 
 Procedure:  
 Assign one gene to each cluster. 
 Calculate the distance D according to equation (3.3) for all pairs of clusters. 
 while there is more than one cluster do 
    Search for a pair of clusters with the minimum distance. 
    If Any pairs of clusters have the same distance then 
     Compare conventional distance of expression levels. 
    end if 
    Merge the clusters. 
    Store the clusters and the distance D in Newick format to N. 
    Calculate the distance D using the equation (3.3) between a new cluster and other clusters. 
 end while 
 return N 
 
3.2.2 Benchmark study of clustering 
For demonstrating the superiority of my method over other methods, I evaluated the accuracy 
of DEclust and of hierarchical clustering performed with conventional distance measures 
(hereafter called existing methods) by using simulated datasets based on assuming RNA-Seq 
analysis. In this benchmark study, I used 12 distance measures as the existing methods: the 
combinations of 4 inter-cluster distances (the group average method, single-linkage method, 
complete-linkage method, and Ward’s method (Ward, 1963)) and 3 inter-gene distances 
(Euclidean distance, Pearson’s correlation, and cosine distance). In the text that follows, I 
denote a DEG as a gene whose expression levels differ in a statistically significant manner 
between at least one pair of conditions. In the benchmark study, I assumed four artificial 
conditions, and for evaluation, I established ten pairwise DET profiles as class labels of 
DEGs (Fig. 3.2) and one pairwise DET profile for non-DEGs (and thus prepared 11 correct 
class labels in total). Moreover, 20% of the genes were randomly selected and a class label 
for DEGs was randomly assigned for each selected gene. Next, I designed the probabilistic 
distributions as controls for each gene to generate simulated datasets of RNA-Seq read counts. 
The RNA-Seq read count data of 69 lymphoblastoid cell lines (LCLs) derived from unrelated 
Nigerian individuals (Pickrell et al., 2010) was used as the reference. The read counts for 
each condition were sampled from the control distribution as many times as the number of 
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replicates, and these were treated as the biological replicates for each condition. Further, the 
read counts for differentially expressed conditions were relative to a certain fold-change in 
concordance with the class label (i.e., with the DET profile). According to the read counts, I 
generated simulated short reads to obtain gene expression profiles for four artificial 
conditions with a certain number of replicates (entire description about simulation datasets is 
presented in section 3.3.1). The simulated reads were mapped to a reference genome, and 
expression levels were estimated for each gene per condition. The statistical tests were 
applied to all pairs of conditions to detect significant differences in gene expression. I 
calculated the pairwise DET profile from the results of the statistical tests and assigned it to 
each gene. Lastly, I implemented DEclust and the existing methods for all of the genes 
expressed in one or more conditions. The estimation of gene expression levels and the 
statistical tests were performed using edgeR (Robinson, McCarthy and Smyth, 2010), DESeq 
(Anders and Huber, 2010), DESeq2 (Love, Huber and Anders, 2014), and cuffdiff2 (Trapnell 
et al., 2013). The inputs of DEclust were the pairwise DET profiles and estimated normalized 
expression levels, and the inputs of the existing methods were the estimated normalized 
expression levels. In this manner, I performed the simulation thrice for each parameter set. As 
a result, I generated three simulation datasets in which the genes belonging to the cluster with 
the same class label and the expression profiles of each gene were different among 
simulations for each parameter set. 
 
Figure 3.2. Ten correct labels of benchmark study. Line plots with corresponding pairwise 
DET profiles. The handling of each dimension is same as Fig. 3.1a. Four of the correct labels 
represent genes that are overexpressed in any one condition (a-d), while four other correct 
labels represent genes that are overexpressed in any two conditions (e-h). The rests of the 
labels represent genes that are overexpressed in any three conditions (i, j). 
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For all pairs of genes featuring identical class labels, I assessed whether they belonged to 
the same resultant cluster after clustering. I converted the clustering problem into a binary 
classification problem, and as a measure of the evaluation, I used the area under the curve 
(AUC) of the receiver operating characteristic (ROC). I calculated the AUCs for each 
parameter set of inter-gene distances, inter-cluster distances, and number of replicates, and 
compared the AUCs between DEclust and the existing methods (Fig. 3.3). Not only did 
DEclust show higher accuracy than the existing methods for almost all parameter sets, the 
AUCs of DEclust were also improved with an increase in the number of replicates. 
Specifically, DEclust showed superior accuracy in all the datasets containing two or more 
replicates when DESeq2 was used for statistical tests. Moreover, the AUCs of DEclust were 
higher than those of the existing methods even when edgeR, DESeq or cuffdiff2 was used 
with sufficient replicates. Thus, DEclust succeeded in identifying the correct class labels of 
differentially expressed patterns from multi-conditional transcriptome data more accurately 
than the existing clustering methods. Conversely, the existing methods showed lower 
accuracy than DEclust in my benchmark dataset. The existing methods depend solely on the 
means of the expression levels; therefore, the existing methods could not distinguish 
significant differences in expression levels from stochastic noise. Consequently, the existing 
methods could not extract statistically overrepresented and differentially expressed gene 
clusters. In either method, the variance of AUCs among the three simulation datasets for each 
parameter set was not so large. 
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Figure 3.3. Results of clustering evaluation. DEclust is my method and existing is 
conventional hierarchical clustering method. For the quantification of the gene expression 
and statistical test to identify the differential expression, DESeq, DESeq2, edgeR, and 
cuffdiff2 were used. For existing methods and secondary distance measure of DEclust, the 
group average, complete-linkage, single-linkage, and Ward’s method (Ward, 1963) were used 
for the inter-cluster distance measure, and the cosine distance, Euclidean distance, and 
Pearson’s correlation were used for the inter-gene distance measure. 
 
To summarize this benchmark study, when any biological replicates were available, the 
highest accuracy was achieved by DEclust with the use of the statistical test results of 
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DESeq2, and when the number of biological replicates was sufficient, DEclust with edgeR 
was most accurate. Furthermore, if optimal statistical test results are obtained, AUC = 1.00 
with my method. 
3.2.3 Benchmark study of DEG detection 
Although DEclust uses the results of statistical tests for all combinatorial pairs of conditions, 
multiDE (Kang, Du and Zhang, 2016) has been proposed to detect DEGs among multiple 
conditions. In addition, edgeR and DESeq2 have an extended function, the likelihood ratio 
test, to detect DEGs among multiple conditions. Therefore, I evaluated the power of DEG 
detection using multiDE, edgeR, DESeq2, and DEclust. For evaluation of the DEG detection 
capability of DEclust, I defined a “DEG cluster” and “non-DEG cluster” as follows. If there 
was at least one element of a pairwise DET profile of a cluster with a value of 1 or −1, the 
cluster was a DEG cluster; otherwise (that is, all elements were 0), it was a non-DEG cluster. 
In this manner, DEclust can be applied to the classification problem of whether a gene is a 
DEG or not. I used the same simulation datasets that were used for the benchmark study to 
evaluate the performance of DEclust and the conventional clustering methods (the details for 
the evaluation method are described in the Materials and Methods). 
 The performance of edgeR, DESeq2, multiDE, and DEclust was evaluated according to the 
true-positive rate (TPR), positive predictive value (PPV), accuracy, and F-measure (harmonic 
mean of TPR and PPV). DEclust uses the pairwise based statistical test results obtained from 
edgeR, DESeq, DESeq2, or cuffdiff2; the evaluation results using each tool are shown 
separately (Fig. 3.4a). Overall, DEclust, based on statistical testing between all pairs of 
conditions, had higher TPR, and edgeR, DESeq2, and multiDE, based on the statistical 
testing for multiple conditions, had higher PPV. Focusing on the F-measure (the harmonic 
mean of TPR and PPV), DEclust with DESeq2, DEclust with edgeR, sole use of DESeq2, 
and sole use of edgeR were advantageous relative to the other methods. Moreover, not only 
was the DEG detection power of DEclust with DESeq2 and sole use of DESeq2 sufficiently 
close, but also DEclust with DESeq2 was advantageous when only a few biological replicates 
were available (Fig. 3.4b). 
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Figure 3.4. Results of DEG detection evaluation. The F-measures, accuracies, TPRs, and 
PPVs for each method for each number of replicates are plotted. The vertical axis shows the 
mean values of corresponding indicator and the error bars are drawn in accordance with the 
corrected sample standard deviation of three simulations for each parameter set. DEclust, my 
method, uses the statistical test results obtained from edgeR, DESeq, DESeq2, or cuffdiff2, 
and the evaluation results using each of these tools are separately shown as “DEclust_[DEGs 
detection tool]”. For the secondary distance of DEclust, the group average method with 
cosine distance was used. The complete results for edgeR, DESeq2, multiDE, and DEclust 
are shown in (a), and only F-measure of DESeq2 and DEclust with DESeq2 are shown in (b). 
 
Although the single statistical test for multiple conditions using edgeR, DESeq2, and 
multiDE can more accurately identify DEGs, statistical tests for all combinatorial pairs of 
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conditions can identify DEGs with higher sensitivity and determine which pairs of conditions 
are significantly different. In the present study, the DEG detection ability of DEclust, which 
was in accordance with the statistical test results for all combinatorial pairs of conditions, was 
comparable with that of tools that detect DEGs among multiple conditions using a single test. 
According to the definition of the pairwise DET profile assigned for each cluster (equation 
(3.2)) and the distance between clusters (equation (3.3)), the distance between DEG clusters 
and non-DEG clusters should be 2 (maximum value) because none of the significant 
statistical test results are shared; therefore, DEclust can accurately cluster the DEGs and 
non-DEGs if quitting the merge step of hierarchical clustering when the distance between any 
pair of clusters n, m satisfies D(Cn, Cm) ≥ 1. Thus, DEclust has high compatibility for 
multi-conditional transcriptome analysis. 
3.2.4 Application to biological data 
To demonstrate the practical usefulness of DEclust, I performed mRNA-Seq analysis on 
mouse tumor samples and applied DEclust to extract statistically overrepresented and 
significant gene clusters among multiple stages in the process of cancer progression. I and 
collaborators obtained normal skin, papilloma, carcinoma, and metastatic tumors from each 
of the same two mice (i.e., two replicates were obtained for each stage), and performed 
mRNA-Seq on these tumor samples. I obtained an average of 40.10 M reads by performing 
mRNA-Seq with an Illumina Genome Analyzer IIx, and I mapped the reads to a mouse 
reference genome (Table 3.1). Subsequently, I identified the genes that were differentially 
expressed between a pair of the four tumorigenesis stages by using DESeq2. In total, 6,584 
DEGs were detected (Table 3.2). 
 Next, I applied DEclust to the detected 6,584 DEGs between a pair of stages using the 
results of DESeq2 to extract statistically overrepresented gene clusters among the four 
tumorigenesis stages. The hierarchical clustering tree of DEGs was calculated, and the DEGs 
were divided into 16 clusters by quitting the merge step if the distance between any pair of 
clusters n, m satisfied D(Cn, Cm) ≥ 1 (Fig. 3.5a). Fig. 3.5b shows the 16 clusters together with 
the corresponding expression patterns and pairwise DET profiles. According to the pairwise 
DET profiles of the 16 clusters, the genes that belong to one of 16 clusters shared at least one 
statistical test result of a pair of stages. Thus, DEclust can extract statistically significant gene 
clusters from multi-conditional transcriptome data. Furthermore, I performed a gene set 
enrichment analysis (GSEA) for each cluster (the top three hallmarks are shown in Table 3.3). 
The genes of each cluster were annotated with hallmarks such as the KRAS signaling pathway, 
mammalian target of rapamycin (mTOR) signaling pathway, and checkpoints of the cell cycle, 
which are typical cancer-related pathways (Vermeulen, Van Bockstaele and Berneman, 2003; 
Vogelstein et al., 2013). 
 
 45 
 
Table 3.1. Statistical summary of mouse mRNA-Seq data. 
  Normal skin Papillomas Carcinomas Metastasis 
Samples Replicate 1 Replicate 2 Replicate 1 Replicate 2 Replicate 1 Replicate 2 Replicate 1 Replicate 2 
# reads 40,133,148 41,321,764 39,146,671 40,790,238 40,500,492 41,275,570 37,819,465 39,833,125 
# passed 35,446,518 37,002,801 35,360,696 36,024,516 35,651,129 36,937,481 34,235,323 36,688,396 
% passed 88.32 89.55 90.33 88.32 88.27 89.49 90.52 92.11 
# mapped 29,260,581 31,015,376 28,866,123 27,802,980 29,631,879 31,901,997 28,255,455 31,387,689 
% mapped 82.54 83.82 81.63 77.18 82.88 86.37 82.53 85.55 
An average of 40.10 M reads was obtained from mRNA-Seq with Illumina Genome Analyzer 
IIx. An average of 89.61% of reads passed a quality filter, and 82.81% of those reads were 
uniquely mapped to mouse reference genome. 
 
Table 3.2. Result of DEG detection for the mouse mRNA-Seq data. 
  
Up-regulated 
Normal skin Papillomas Carcinomas Metastasis 
Down-regulated 
Normal skin   1,464 1,535 1,405 
Papillomas 1,668   886 1,428 
Carcinomas 1,596 798   766 
Metastasis 1,358 1139 579   
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Figure 3.5. Cancer transcriptome analysis using DEclust. (a) Hierarchical tree of clustering 
result from DEclust for the transcriptome data. The vertical axis indicates inter-cluster 
distance (equation (3.3)). The DEGs are divided into 16 clusters (which are color-coded). The 
cluster numbers correspond to the numbers in Table 3.3, and each cluster is assigned a 
pairwise DET profile of six dimensions. (b) Line plots of the expression patterns for each 
gene in each. 
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Table 3.3. Result of GSEA for each cluster obtained by using DEclust. 
Cluster # genes 
6 dim pattern 
Note GSEA Hallmarks 
NP NC NM PC PM CM 
1 373 (0 0 0 0 -1 0) P > M MTORC1_SIGNALING, E2F_TARGETS, MYC_TARGETS_V1 
2 96 (0 0 0 -1 0 0) P > C 
ADIPOGENESIS, MITOTIC_SPINDLE, 
ESTROGEN_RESPONSE_EARLY 
3 117 (0 0 0 0 0 1) C < M HEME_METABOLISM, XENOBIOTIC_METABOLISM 
4 727 (1 0 0 0 0 0) N < P E2F_TARGETS, MTORC1_SIGNALING, MYC_TARGETS_V1 
5 345 (1 0 0 0 -1 0) 
N < P E2F_TARGETS, MYC_TARGETS_V1,  
P > M MTORC1_SIGNALING 
6 965 (0 -1 -1 0 0 0) 
N > C MYOGENESIS, HYPOXIA,  
N > M ESTROGEN_RESPONSE_LATE 
7 328 (0 -1 0 0 0 0) N > C 
ADIPOGENESIS, COMPLEMENT,  
PI3K_AKT_MTOR_SIGNALING 
8 721 
            
N > P 
MYOGENESIS, INTERFERON_GAMMA_RESPONSE, 
(-1 0 0 0 0 0) EPITHELIAL_MESENCHYMAL_TRANSITION 
9 143 (0 0 -1 0 0 0) N > M G2M_CHECKPOINT, MYOGENESIS, HEME_METABOLISM 
10 490 (0 0 1 0 1 0) 
N < M COMPLEMENT, COAGULATION,  
P < M ESTROGEN_RESPONSE_EARLY 
11 742 (0 0 0 0 1 0) P < M 
BILE_ACID_METABOLISM, UV_RESPONSE_DN, 
INTERFERON_GAMMA_RESPONSE 
12 238 (0 0 1 0 0 0) N < M 
XENOBIOTIC_METABOLISM, ADIPOGENESIS, 
REACTIVE_OXIGEN_SPECIES_PATHWAY 
13 140 (0 0 0 1 0 0) P < C 
INFLAMMATORY_RESPONSE, COMPLEMENT, 
IL6_JAK_STAT3_SIGNALING 
14 46 (0 0 0 0 0 -1) C > M EPITHELIAL_MESENCHYMAL_TRANSITION 
15 577 (0 1 1 0 0 0) 
N < C EPITHELIAL_MESENCHYMAL_TRANSITION, 
N < M KRAS_SIGNALING_UP, INFLAMMATORY_RESPONSE 
16 536 
            
N < C 
EPITHELIAL_MESENCHYMAL_TRANSITION, 
(0 1 0 0 0 0) KRAS_SIGNALING_UP,  
            INFLAMMATORY_RESPONSE 
In this table, the ‘N’ means normal skin, ‘P’ means papilloma, ‘C’ means carcinoma, and ‘M’ 
means metastatic tumor. The six-dimensional patterns are corresponding to the pairwise DET 
profiles for each cluster. The column “Note” represents an interpretation of the pairwise DET 
profile, and the column “GSEA Hallmarks” shows the top three hallmarks for each cluster. 
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To compare DEclust and an existing method with the use of the real dataset, I performed 
hierarchical clustering using the group average method with the cosine distance for the 6,584 
DEGs and plotted the hierarchical tree (Fig. 3.6a). The hierarchical tree was cut into 16 
clusters to obtain the same number of clusters as in the analysis performed with DEclust. As a 
result of the assignment of a pairwise DET profile to each cluster, all of the elements in the 
assigned pairwise DET profiles were zero (Fig. 3.6b). This means that when the existing 
method was used, the genes showing significant differences and the genes showing 
non-significant differences in expression levels at the same pair of stages were mixed in the 
same cluster. Notably, the existing method could not distinguish significant expression 
differences from noise. Moreover, I performed the GSEA for each cluster generated by the 
existing method and obtained the top three hallmarks for each cluster (Table 3.4). A 
comparison of the results obtained by DEclust and the existing method revealed that any 
cluster obtained by DEclust was annotated but several clusters obtained by the existing 
method could not be annotated because the genes belonging to these clusters were not 
significantly enriched for biological functions. In addition, interleukin-6/Janus kinase/signal 
transducer and activator of transcription-3 (IL6/JAK/STAT3) and phosphatidylinositol 
3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling 
pathways were detected only by DEclust. These pathways not only are frequently activated in 
cancer cells, but are also involved in cancer progression by promoting tumor cell growth, 
angiogenesis, and metastasis (Porta, Paglino and Mosca, 2014; Yu et al., 2014). Thus, 
DEclust can extract biologically significant gene clusters. 
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Figure 3.6. Result of hierarchical clustering by using existing clustering method. (a) 
Hierarchical tree generated by the existing clustering method with the group average method 
for inter-cluster distance measure and the cosine distance for inter-gene distance measure. 
The clusters were divided at the highlighted in blue dotted lines. The cluster numbers are 
assigned to left to right cluster. (b) Line plots of the expression patterns for each gene in each 
cluster. The annotations in the bottom of figures are a cluster number associated with S11 
Table and their pairwise DET profiles. 
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Table 3.4. Result of GSEA for each cluster obtained by using existing method. 
Cluster # genes 
6 dim pattern 
Note GSEA Hallmarks 
NP NC NM PC PM CM 
1 1250 (0 0 0 0 0 0) N.A. 
MYOGENESIS, ESTROGEN_RESPONSE_EARLY, 
ESTROGEN_RESPONSE_LATE 
2 34 (0 0 0 0 0 0) N.A. -- 
3 95 (0 0 0 0 0 0) N.A. 
UV_RESPONSE_DN, INFLAMMATORY_RESPONSE, 
EPITHELIAL_MESENCHYMAL_TRANSITION 
4 125 (0 0 0 0 0 0) N.A. 
FATTY_ACID_METABOLISM, ADIPOGENESIS 
KRAS_SIGNALING_DN 
5 47 (0 0 0 0 0 0) N.A. -- 
6 675 (0 0 0 0 0 0) N.A. 
HEME_METABOLISM, UV_RESPONSE_DN,  
TNFA_SIGNALING_VIA_NFKB 
7 634 (0 0 0 0 0 0) N.A. 
XENOBIOTIC_METABOLISM,  
ESTROGEN_RESPONSE_EARLY, COAGULATION 
8 376 (0 0 0 0 0 0) N.A. 
KRAS_SIGNALING_UP, INTERFERON_ALPHA_RESPONSE, 
INTERFERON_GAMMA_RESPONSE 
9 97 (0 0 0 0 0 0) N.A. 
TGF_BETA_SIGNALING, UV_RESPONSE_DN 
INFLAMMATORY_RESPONSE 
10 346 (0 0 0 0 0 0) N.A. 
FATTY_ACID_METABOLISM, BILE_ACID_METABOLISM, 
INTERFERON_ALPHA_RESPONSE 
11 508 (0 0 0 0 0 0) N.A. 
EPITHELIAL_MESENCHYMAL_TRANSITION 
INFLAMMATORY_RESPONSE, KRAS_SIGNALING_UP 
12 534 (0 0 0 0 0 0) N.A. 
EPITHELIAL_MESENCHYMAL_TRANSITION 
KRAS_SIGNALING_UP, INFLAMMATORY_RESPONSE 
13 157 (0 0 0 0 0 0) N.A. 
CHOLESTEROL_HOMEOSTASIS, APICAL_JUNCTION, 
XENOBIOTIC_METABOLISM 
14 303 (0 0 0 0 0 0) N.A. 
XENOBIOTIC_METABOLISM 
TGF_BETA_SIGNALING, ADIPOGENESIS 
15 315 (0 0 0 0 0 0) N.A. G2M_CHECKPOINT, E2F_TARGETS, MITOTIC_SPINDLE 
16 1088 (0 0 0 0 0 0) N.A. E2F_TARGETS, MYC_TARGETS_V1, MTORC1_SIGNALING 
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3.3 Materials and Methods 
3.3.1 Simulation datasets 
To evaluate DEclust and conventional clustering methods, I generated simulated short reads 
from mouse reference cDNA sequences so that gene expression profiles for four artificial 
conditions were obtained. I set up ten pairwise DET profiles as correct labels for DEGs (Fig. 
3.2). Four of the correct labels represent genes that are overexpressed in any one condition 
(clusters 1-4), while four other correct labels represent genes that are overexpressed in any 
two conditions (clusters 5-8). The rests of the correct labels represent genes that are 
overexpressed in any three conditions (clusters 9 and 10). Second, 20% of genes were 
randomly selected as DEGs and the correct label for DEGs was randomly assigned for each 
selected gene. Other genes were classified in cluster 0 whose pairwise DET profile is defined 
as (0 0 0 0 0 0), indicating that the expression levels of any pairs of conditions are not 
significantly different. Third, a control distribution that follows the negative binomial 
distribution was generated for each gene. The RNA-Seq read counts for each condition were 
sampled as many times as the number of replicates from the control distribution, and the read 
counts for differentially expressed conditions were biased by a randomly selected 
fold-change. The fold-change was selected from a pool of (×1.5, ×2.0, ×2.5, ×3.0). 
 I generated the control distribution for each gene as follows. First, I downloaded a mouse 
reference genome, mouse reference cDNA, and mouse gene annotation file from Ensembl 
(http://www.ensembl.org/index.html, GRCm38-release71), and RNA-Seq read count data of 
69 Nigerian lymphoblastoid cell lines (LCLs) from Pickrell et al. (Pickrell et al., 2010) to 
yield practical datasets. I extracted genes whose total exon lengths are greater than 200bp 
from the Pickrell et al. data. I calculated a fragments per kilobase of exons per million 
mapped fragments (FPKM) (Trapnell et al., 2010) for each gene as follows: 
FPKM+,x = 10y*+,xMxL+ 			(3.4). 
The FPKM is commonly used to convert the RNA-Seq read counts to comparable 
normalized expression values. Where xi, j represents the number of reads mapped to a gene i 
of a sample j. Mj is a total number of reads for a sample j, and Li is a total exon length of a 
gene i. 10y represents a normalization coefficient for the exon length and the total number 
of reads. From the FPKM of each sample, the mean and variance of the FPKM values for 
each gene were calculated and paired as FPKM statistics data. The FPKM statistics data were 
filtered if the means of the FPKM were less than one. Second, the FPKM statistics data and 
mouse cDNA sequence were matched so that the total exon length of the original gene of the 
FPKM statistics data and the total length of the mouse cDNA sequence are nearest. As a 
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result, 14,907 combinations of the FPKM statistics data and mouse cDNA sequence were 
obtained. 
 The control distributions were generated based on the FPKM statistics data, which contain 
the mean and variance of the FPKM values. I calculated the mean and variance of read counts 
from the mean and variance of FPKM values as follows (the detail of an equation conversion 
is shown at the end of this section): 
{|*+,x∈b} = MbL+10y {|FPKM+,x∈b}			(3.5) 
~Ä|*+,x∈b} = UMbL+10y X\ ~Ä|FPKM+,x∈b}			(3.6), 
where Mk represents the number of total reads for any samples of a condition k. In this 
benchmark study, the numbers of the total reads were assumed to be evenly distributed 
among samples. According to the mean and variance of the read counts, I generated a 
probabilistic distribution as the control distribution, which follows the negative binomial 
distribution. Finally, the read counts were sampled from the control distribution as many 
times as the number of replicates, and the RNA-Seq reads were generated from the matched 
mouse cDNA sequence as mentioned above. Thus, I simulated 14,907 mouse transcripts 
(genes) RNA-Seq datasets for my benchmark study. 
 As to generate datasets, the total number of reads for each sample was simulated 
approximately 1.0 × 107, the single-end RNA-Seq reads with 120 bp of length were generated 
in accordance with the read counts. For each condition, the sampling of the read count was 
repeated with the number of replicates progressively ranging from 1-6, 12, 18, and 24. 
Moreover, I simulated three times for each parameter set. 
 At the end of this section, the equation conversion from the mean and variance of the FPKM 
(equation 3.4) to the mean and variance of read counts can be performed as follows: 
{|FPKM+,x∈b} = 1Ç(É10y*+,VMbL+ ÑV∈b 	
= 10yMbL+ 1Ç(*+,VV∈b 	= 10yMbL+ {|*+,x∈b}	∴ {|*+,x∈b} = MbL+10y {|FPKM+,x∈b} 
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~Ä|FPKM+,x∈b} = 1Ç − 1(F{|FPKM+,x∈b} − FPKM+,VL\V∈b 	
= (10y MbL+⁄ )\Ç − 1 (á1Ç(*+,c − *+,Vc∈b à
\
V∈b 	= (10y MbL+⁄ )\	~Ä|*+,x∈b} 
∴ ~Ä|*+,x∈b} = UMbL+10y X\ ~Ä|FPKM+,x∈b} 
 
 
 
3.3.2 Analysis for benchmark study of clustering 
For the benchmark study of clustering, simulated reads were mapped to a mouse reference 
genome (GRCm38-release71) with a gene annotation file by using TopHat2 (Kim et al., 
2013) (version-2.0.8) with Bowtie2 (Langmead and Salzberg, 2012) (version-2.1.0). The 
gene annotations were confined to 14,907 simulated gene annotations. In this benchmark 
study, edgeR (Robinson, McCarthy and Smyth, 2010), DESeq (Anders and Huber, 2010), 
DESeq2 (Love, Huber and Anders, 2014), and cuffdiff2 (Trapnell et al., 2013) were used as 
statistical tools for detecting significant differential expression between a pair of conditions. 
At the start of the differential expression analysis, HTSeq (Anders, Pyl and Huber, 2015) 
(version-0.6.1) was used with the aforementioned confined gene annotation file to count 
mapped reads for each gene per condition. Subsequently, edgeR (version-3.6.8), DESeq 
(version-1.16.0), and DESeq2 (version-1.4.5) were used to apply statistical tests for all pairs 
of conditions to detect significant differential expression. Correspondingly, cuffdiff2 
(version-2.2.1) was used with the confined gene annotation file to estimate expression levels 
and to apply statistical tests. For correcting the multiple testing of differential expression 
using four tools, I controlled the false discovery rate (FDR). The null hypothesis for multiple 
conditions was “the expression level of a gene is not different in any of the experimental 
conditions”; therefore, I estimated the FDR from (total number of genes) × (total number of 
pairs of conditions) null hypotheses, and controlled it to under 5% by using the 
Benjamini-Hochberg method (Benjamini and Hochberg, 1995). The adjusted p-values were 
calculated by using R package p.adjust. Consequently, normalized expression values and 
statistical test results for each gene were obtained from each differential expression analysis 
tool. Lastly, DEclust and conventional hierarchical clustering algorithms (existing methods) 
were applied to genes whose normalized expression values were non-zero in at least one 
condition. For applying DEclust, the statistical test results for each gene were discretized and 
vectorized to pairwise DET profiles. The group average method, single-linkage method, 
complete-linkage method, and Ward’s method (Ward, 1963) were used for inter-cluster 
distance measures, and the Euclidean distance, Pearson’s correlation, and cosine distance 
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were used for inter-gene distance (or similarity) measures for the existing method and for 
DEclust as secondary distance measures. 
3.3.3 Evaluation of clustering accuracy 
For all pairs of genes featuring identical class labels, I assessed whether they belonged to the 
same cluster after clustering. The pairs of genes that featured identical class labels and 
belonged to the same cluster were true positives. The pairs of genes that featured distinct 
labels and belonged to different clusters were true negatives. The pairs of genes that featured 
the same labels but belonged to different clusters were false negatives. The pairs of genes that 
featured distinct labels but belonged to the same clusters were false positives. Thus, I 
converted the clustering problem into a binary classification problem. The true-positive rate 
(TPR; true positive / condition positive) and the false-positive rate (FPR; false positive / 
condition negative) were calculated at each merging step in hierarchical clustering. An ROC 
curve was created by plotting the TPR against the FPR, and the AUC of the ROC was used as 
a measure for clustering evaluation. 
3.3.4 Analysis for benchmark study of DEG detection 
For the benchmark study of DEG detection, I used the same simulation datasets that were 
used for the benchmark study of clustering. In the same manner as the analysis for the 
benchmark study of clustering, the simulated reads were mapped to a mouse reference 
genome, the read counts of each gene per condition were obtained by using HTSeq, and 
edgeR, DESeq, DESeq2, and cuffdiff2 were applied for statistical testing for all pairs of 
conditions and to calculate the normalized expression values for each condition. 
Subsequently, DEclust was applied to divide 14,907 simulated genes into clusters by quitting 
the merge step if the distance between any pair of clusters n, m satisfied D(Cn, Cm) ≥ 1. 
Separately, the statistical tests for multiple conditions were performed by using edgeR, 
DESeq2, or multiDE (Kang, Du and Zhang, 2016) (version-1.0). 
3.3.5 Evaluation of DEG detection accuracy 
For evaluation of the DEG detection power of DEclust, I defined a “DEG cluster” and 
“non-DEG cluster”. If at least one element of a pairwise DET profile of a cluster was 1 or −1, 
the cluster was a DEG cluster; otherwise (that is, all elements were 0), it was a non-DEG 
cluster. I defined whether a gene was selected as a DEG in a simulation as the correct label, 
and tested whether a gene belonged to a DEG cluster or non-DEG cluster obtained by using 
DEclust; therefore, if a gene was selected as a DEG and it belonged to any of the DEG 
clusters, it was a true positive. If a gene was not selected as a DEG and it belonged to any of 
the non-DEG clusters, it was a true negative. If a gene was not selected as a DEG but 
belonged to any of the DEG clusters, it was a false positive, and a gene selected as a DEG but 
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that belonged to any of the non-DEG clusters was a false negative. For evaluation of the tools 
for detecting DEGs among multiple conditions, I defined whether a gene was selected as a 
DEG as the correct label, and tested whether a gene was detected as a DEG. Therefore, if a 
gene was simulated as a DEG and was detected as a DEG by a tool, it was true positive. If a 
gene was not simulated as a DEG and was not detected as a DEG, it was true negative. If a 
gene was not simulated as a DEG but was detected as a DEG, it was false-positive. If a gene 
was simulated as a DEG but was not detected as a DEG, it was false-negative. I evaluated 
edgeR, DESeq2, multiDE, and DEclust according to the true-positive rate (TPR), positive 
predictive rate (PPV), accuracy, and F-measure (harmonic mean of TPR and PPV). 
3.3.6 Mice 
This study was conducted in strict accordance with the recommendations in the Guide for the 
Care and Use of Laboratory Animals of the Ministry of Education, Culture, Sports, Science, 
and Technology of Japan. The protocol was approved by the Committee on the Ethics of 
Animal Experiments of Chiba Cancer Center (Permit Number: 16–15). All efforts were made 
to minimize suffering. FVB/N mice were purchased from CLEA Japan, Tokyo, Japan. 
3.3.7 Skin carcinogenesis and tumor sampling 
DMBA (7,12-dimethylbenz(a)anthracene) was used as a carcinogen and TPA 
(12-O-tetradecanoylphorbol-13-acetone) was used as a promoter. Collaborators treated 17 
FVB/N mice according to a two-stage carcinogenesis protocol. At 8 weeks of age, the female 
mice were carefully shaved with electric clippers, and two days after shaving, a single dose of 
DMBA (25 µg/mouse in 200 µL of acetone) was applied to the shaved dorsal back skin. One 
week after initiation, tumors were promoted with TPA (10 µg/mouse in 200 µL of acetone) 
twice weekly for 20 weeks. The number and size (diameter, in mm) of each papilloma were 
recorded from 8 until 20 weeks, and carcinoma development was monitored for up to 40 
weeks post-TPA treatment. The health of the mice was monitored every day by laboratory 
animal technicians. The mice were sacrificed by cervical dislocation when the tumor volume 
reaches 10% of the individual’s body weight. Lastly, normal skin, papilloma, carcinoma, and 
metastatic tumor samples were collected from each of two mice (two biological replicates, 
four stages). 
3.3.8 Sample preparation and mRNA-Seq 
Total RNA was extracted from the papillomas, carcinomas, metastatic tumors, and normal 
tissues by using the AGPC (acid guanidinium thiocyanate-phenol-chloroform) method 
(Chomczynski, 1993), and the total RNA samples were treated with DNase to eliminate 
genomic DNA. Each RNA sample was then reverse-transcribed using the SMARTER® 
UltraTM Low RNA Kit (634935; Takara, Otsu, Japan); 10 ng of total RNA was used and PCR 
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was performed for 12 cycles. The products were treated according to the TruSeqTM DNA 
Sample Preparation v2 Guide for Illumina sequencing. In this step, PCR was performed for 
15 cycles. Lastly, mRNA-Seq was performed using the Illumina Genome Analyzer IIx for 
eight samples (two replicates, four stages) according to the cBot workflow and Genome 
Analyzer IIx Paired End Run workflow. For each sample, 84 bp single-end reads were 
obtained. 
3.3.9 RNA-Seq data analysis 
Low-quality mRNA-Seq reads were filtered by using FASTX-Toolkit 
(http://hannonlab.cshl.edu/fastx_toolkit/index.html) with the options -q 20 and -p 80. The 
remaining reads were mapped to the mouse reference genome (GRCm38-release71.fa) with 
gene annotation (Mus musculus.GRCm38.71.gtf) by using TopHat2 (version-2.0.8) with 
Bowtie2 (version-2.1.0). To identify significant differential expression, HTSeq 
(version-0.6.1) and DESeq2 (version-1.4.5) were used with the FDR controlled to <5%. 
DEclust was applied to the results of DESeq2, and a hierarchical tree of genes was calculated. 
The group average method with cosine distance was used for a secondary distance measure if 
any pairs of clusters featured the same distance under the definition of equation (3.3) (S1 
Text). The final clusters were determined by quitting the merge step if the distance between 
any pair of clusters n, m satisfied D(Cn, Cm) ≥ 1. The discriminative genes among 
tumorigenesis stages were investigated using a GSEA software (Subramanian et al., 2005) for 
each stage and cluster. Hallmark gene sets were used and the gene sets with an FDR q-value 
below 5% were identified; these were coherently expressed signatures derived by aggregating 
several Molecular Signatures Database gene sets. Moreover, the conventional hierarchical 
clustering method (the group average method with cosine distance) was applied to the 
detected DEGs for a comparison with the results obtained using DEclust. The hierarchical 
tree was cut into 16 clusters to obtain the same number of clusters as in the analysis with 
DEclust, and the GSEA was performed on each gene cluster. 
3.3.10 Data deposition 
The source code of DEclust and other related data are deposited in the web site 
(http://www.dna.bio.keio.ac.jp/software/DEclust) and the Mendeley Data web site 
(http://dx.doi.org/10.17632/wdfb5w7vbb.1, DOI: 10.17632/wdfb5w7vbb.1). All mRNA-Seq 
reads have been deposited in the Read Archive at DDBJ (Accession number DRA005289). 
3.4 Conclusion 
In this chapter, I proposed a novel transcriptome analysis method, DEclust, to search for 
differentially expressed and statistically overrepresented patterns of gene expression profiles 
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among multiple experimental conditions. The results of the benchmark study showed not 
only that DEclust can extract statistically significant gene clusters from multi-conditional 
transcriptome data more accurately than conventional clustering methods, but also that the 
accuracy of DEclust increases if two or more replicates of the quantitative experiments are 
available. Moreover, the results of the application to biological data (mRNA-Seq analysis of 
mouse tumorigenesis stages) suggested that DEclust can potentially yield biologically 
significant gene clusters. 
 The ready availability of high-throughput sequencing technologies has facilitated large-scale 
quantitative analyses in all fields of life science. As a result, I expect increased demand for 
software that is applicable to multi-conditional studies. DEclust can be applied to any 
multi-conditional transcriptome data, and to the results of any DEG detection tool given an 
appropriate input format; thus, DEclust can be used for a wide range of applications for 
transcriptome data analysis into the future. The computational complexity of DEclust is 
O(N3), where N is the number of objects (genes). The distances between all pairs of clusters 
(equation (3.3)) must be updated in every iteration of hierarchical clustering. As a reference, 
when I performed the mouse transcriptome analysis, the computational time of DEclust was 
approximately ten minutes for 6,584 DEGs with 8 threads of Opteron 1.4 GHz CPUs. The 
source code of DEclust is freely available at http://www.dna.bio.keio.ac.jp/software/DEclust 
or http://dx.doi.org/10.17632/wdfb5w7vbb.1. DEclust is implemented using C++ with boost 
C++ library (http://www.boost.org/) and OpenMP (http://openmp.org/wp/). 
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Chapter 4 
Conclusion and future work 
In this dissertation, I have presented the studies analyzing the process of cancer progression. 
My aim is to understand the entire process of tumorigenesis by a longitudinal approach that is 
complementary to existing cross-cancer-sectional approach of tumors. I conducted genome 
and transcriptome sequencing analysis for the tumors obtained by the experimental 
carcinogenesis of mice. 
 I have described the results of cancer genome study in Chapter 2 and cancer transcriptome 
study in Chapter 3. Through these studies, I gave insights of the evolutional process in the 
tumors over time and the gene clusters whose expression patterns were discriminative in the 
process of the tumor progression (Fig. 4.1). The results of the genome analysis (Chapter 2) 
suggested that each of the tumor-series acquired and inherited different mutations, and the 
intra-tumor structure of the malignant series had been dramatically changed between 9th and 
14th weeks. The results of the transcriptome analysis (Chapter 3) suggested that each tumor 
progression stage has different gene expression profile, meaning that different genes were 
activated in each of the stages. 
 
Figure 4.1. Summary of the genome and transcriptome studies. The results of the genome 
analysis suggested that each of the tumor-series acquired and inherited different mutations, 
and the intra-tumor structure of the malignant series had been dramatically changed between 
9th and 14th weeks. The results of the transcriptome analysis suggested that each tumor 
progression stage has different gene expression profile. 
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In the light of the initial purpose of this dissertation, I and my collaborators were able to 
advance understanding the entire process of tumor progression through conducting each of 
the omics studies. An example of the research that directly analyzes the process of tumor 
progression is few; hence, my results are meaningful and I consider that it is necessary to 
advance such a direct approach to reveal the entire process of cancer progression. 
 As I described in Chapter 1, the inter- and intra-tumor heterogeneity make it difficult to 
understand cancer disease. Since each tumor evolves with the accumulation of different 
mutations, it is indispensable to investigate numerous tumors with diverse fates for full 
understanding of the entire evolutional process in tumors. In this point, my studies are only 
case studies, so I am now planning to scale up by increasing the number of mouse individuals 
to obtain >50 tumor-series. Moreover, the extension of the targeted genome sequencing to 
WGS or WES can be considered. Recent improvement of sequencing technologies has 
provided a reduction in cost to the amounts of short-reads. Although the targeted sequencing 
technology I adopted allows deep sequencing for the targeted genomic region at low cost, I 
predict that equivalent read coverage on a whole genome scale will be practically obtainable 
in the near future. Furthermore, integrative analysis of genomic mutations and transcriptome 
dynamics can be considered for more precise detection of the cancer drivers, selective events, 
and fate determination of tumors. These scale-up of the analysis objects and analysis methods 
should lead to a comprehensive understanding of tumorigenesis process. 
 To be more specific, I am planning to infer intra-tumor evolutionary trees based on genomic 
mutations for various tumors by WGS or WES analysis. From the changes of the 
evolutionary trees with time differences between tumors, I can know when and what kind of 
sub-clones produce malignant tumors. Furthermore, with reference to the transcriptome 
dynamics, I can clarify the cause and the timing of the cancer driver events and the fate 
determination of tumors at the genetic level. I consider that these future results should 
contribute not only to reveal the entire process of tumor progression, but also to provide 
biomarkers for early diagnosis and early treatment. 
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Appendix B – Supplementary information of genome analysis 
 
Supplementary Figure S2.1. Photographic images of papillomas and carcinoma in the 
two-stage skin carcinogenesis by DMBA-TPA protocol. Papillomas appear as outgrowths on 
the dorsal back skin of mouse. The blue circles indicate malignant series tumor. The pink 
circles indicate regressed series tumors. Scale bar = 20 mm. 
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Supplementary Table S2.1. List of target genes. 
ENSEMBL GENE ID GENE SYMBOL ENSEMBL GENE ID GENE SYMBOL 
ENSMUSG00000000088 Cox5a ENSMUSG00000028465 Tln1 
ENSMUSG00000000326 Comt ENSMUSG00000028478 Clta 
ENSMUSG00000000346 Dazap2 ENSMUSG00000028530 Jak1 
ENSMUSG00000000530 Acvrl1 ENSMUSG00000028648 Ndufs5 
ENSMUSG00000000568 Hnrnpd ENSMUSG00000028670 Lypla2 
ENSMUSG00000000581 C1d ENSMUSG00000028691 Prdx1 
ENSMUSG00000000594 Gm2a ENSMUSG00000028692 Akr1a1 
ENSMUSG00000001016 Ilf2 ENSMUSG00000028745 Capzb 
ENSMUSG00000001082 Mfsd10 ENSMUSG00000028755 Cda 
ENSMUSG00000001119 Col6a1 ENSMUSG00000028757 Ddost 
ENSMUSG00000001127 Araf ENSMUSG00000028798 Eif3i 
ENSMUSG00000001150 Mcm3ap ENSMUSG00000028809 Srrm1 
ENSMUSG00000001270 Ckb ENSMUSG00000028811 Yars 
ENSMUSG00000001289 Pfdn5 ENSMUSG00000028837 Psmb2 
ENSMUSG00000001416 Cct3 ENSMUSG00000028893 Sesn2 
ENSMUSG00000001472 Tcf25 ENSMUSG00000028955 Vamp3 
ENSMUSG00000001517 Foxm1 ENSMUSG00000028964 Park7 
ENSMUSG00000001761 Smo ENSMUSG00000028980 H6pd 
ENSMUSG00000001786 Fbxo7 ENSMUSG00000028991 Mtor 
ENSMUSG00000001833 Sept7 ENSMUSG00000028998 Tomm7 
ENSMUSG00000001847 Rac1 ENSMUSG00000029020 Mfn2 
ENSMUSG00000001870 Ltbp1 ENSMUSG00000029062 Cdk11b 
ENSMUSG00000002015 Bcap31 ENSMUSG00000029070 Mxra8 
ENSMUSG00000002413 Braf ENSMUSG00000029106 Add1 
ENSMUSG00000002504 Slc9a3r2 ENSMUSG00000029131 Dnajb6 
ENSMUSG00000002524 Puf60 ENSMUSG00000029231 Pdgfra 
ENSMUSG00000002768 Mea1 ENSMUSG00000029465 Arpc3 
ENSMUSG00000002778 Kdelr1 ENSMUSG00000029472 Anapc5 
ENSMUSG00000002814 Top3a ENSMUSG00000029538 Srsf9 
ENSMUSG00000002949 Timm44 ENSMUSG00000029580 Actb 
ENSMUSG00000003037 Rab8a ENSMUSG00000029616 Erp29 
ENSMUSG00000003068 Stk11 ENSMUSG00000029623 Pdap1 
ENSMUSG00000003072 Atp5d ENSMUSG00000029713 Gnb2 
ENSMUSG00000003344 Btbd2 ENSMUSG00000030007 Cct7 
ENSMUSG00000003378 Grik5 ENSMUSG00000030120 Mlf2 
ENSMUSG00000003380 Rabac1 ENSMUSG00000030180 Kdm5a 
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ENSMUSG00000003402 Prkcsh ENSMUSG00000030201 Lrp6 
ENSMUSG00000003410 Elavl3 ENSMUSG00000030246 Ldhb 
ENSMUSG00000003528 Slc25a1 ENSMUSG00000030265 Kras 
ENSMUSG00000003813 Rad23a ENSMUSG00000030337 Vamp1 
ENSMUSG00000003868 Ruvbl2 ENSMUSG00000030591 Psmd8 
ENSMUSG00000003970 Rpl8 ENSMUSG00000030602 Pak4 
ENSMUSG00000004054 Map3k11 ENSMUSG00000030678 Maz 
ENSMUSG00000004264 Phb2 ENSMUSG00000030795 Fus 
ENSMUSG00000004937 Sgta ENSMUSG00000030849 Fgfr2 
ENSMUSG00000005043 Sgsh ENSMUSG00000030890 Ilk 
ENSMUSG00000005054 Cstb ENSMUSG00000030954 Gp2 
ENSMUSG00000005103 Wdr1 ENSMUSG00000031024 St5 
ENSMUSG00000005198 Polr2a ENSMUSG00000031029 Eif3f 
ENSMUSG00000005370 Msh6 ENSMUSG00000031066 Usp11 
ENSMUSG00000005483 Dnajb1 ENSMUSG00000031167 Rbm3 
ENSMUSG00000005540 Fcer2a ENSMUSG00000031207 Msn 
ENSMUSG00000005566 Trim28 ENSMUSG00000031311 Nono 
ENSMUSG00000005575 Ube2m ENSMUSG00000031447 Lamp1 
ENSMUSG00000005610 Eif4g2 ENSMUSG00000031511 Arhgef7 
ENSMUSG00000005621 Zfp592 ENSMUSG00000031535 Dkk4 
ENSMUSG00000005672 Kit ENSMUSG00000031586 Rbpms 
ENSMUSG00000005779 Psmb4 ENSMUSG00000031672 Got2 
ENSMUSG00000005871 Apc ENSMUSG00000031729 Ist1 
ENSMUSG00000006057 Atp5g1 ENSMUSG00000031760 Mt3 
ENSMUSG00000006095 Tbcb ENSMUSG00000031776 Arl2bp 
ENSMUSG00000006304 Arpc2 ENSMUSG00000031785 Gpr56 
ENSMUSG00000006315 Tmem147 ENSMUSG00000031788 Kifc3 
ENSMUSG00000006333 Rps9 ENSMUSG00000031818 Cox4i1 
ENSMUSG00000006344 Ggt5 ENSMUSG00000031839 Hsbp1 
ENSMUSG00000006498 Ptbp1 ENSMUSG00000031948 Kars 
ENSMUSG00000006932 Ctnnb1 ENSMUSG00000031950 Gabarapl2 
ENSMUSG00000007458 M6pr ENSMUSG00000031990 Jam3 
ENSMUSG00000007564 Ppp2r1a ENSMUSG00000031996 Aplp2 
ENSMUSG00000007850 Hnrnph1 ENSMUSG00000032085 Tagln 
ENSMUSG00000007872 Id3 ENSMUSG00000032115 Hyou1 
ENSMUSG00000007891 Ctsd ENSMUSG00000032231 Anxa2 
ENSMUSG00000008036 Ap2s1 ENSMUSG00000032294 Pkm 
ENSMUSG00000008958 Vps72 ENSMUSG00000032312 Csk 
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ENSMUSG00000009073 Nf2 ENSMUSG00000032330 Cox7a2 
ENSMUSG00000009090 Ap1b1 ENSMUSG00000032356 Rasgrf1 
ENSMUSG00000009291 Pttg1ip ENSMUSG00000032423 Syncrip 
ENSMUSG00000009470 Tnpo1 ENSMUSG00000032479 Mtap4 
ENSMUSG00000009549 Srp14 ENSMUSG00000032480 Dhx30 
ENSMUSG00000009630 Ppp2cb ENSMUSG00000032498 Mlh1 
ENSMUSG00000009927 Rps25 ENSMUSG00000032562 Gnai2 
ENSMUSG00000010097 Nxf1 ENSMUSG00000032637 Atxn2l 
ENSMUSG00000010376 Nedd8 ENSMUSG00000032737 Inppl1 
ENSMUSG00000012405 Rpl15 ENSMUSG00000032845 Alpk2 
ENSMUSG00000012535 Tnpo3 ENSMUSG00000033020 Polr2f 
ENSMUSG00000012848 Rps5 ENSMUSG00000033068 Entpd6 
ENSMUSG00000013663 Pten ENSMUSG00000033159 Cnppd1 
ENSMUSG00000014294 Ndufa2 ENSMUSG00000033379 Atp6v0b 
ENSMUSG00000014426 Map3k4 ENSMUSG00000033430 Terf2ip 
ENSMUSG00000014599 Csf1 ENSMUSG00000033569 Bai3 
ENSMUSG00000014606 Slc25a11 ENSMUSG00000033809 Alg3 
ENSMUSG00000014748 Tex261 ENSMUSG00000033826 Dnahc8 
ENSMUSG00000014769 Psmb1 ENSMUSG00000033916 Chmp2a 
ENSMUSG00000014859 E2f4 ENSMUSG00000033938 Ndufb7 
ENSMUSG00000015120 Ube2i ENSMUSG00000034165 Ccnd3 
ENSMUSG00000015291 Gdi1 ENSMUSG00000034210 4732418C07Rik 
ENSMUSG00000015605 Srf ENSMUSG00000034659 Tmem109 
ENSMUSG00000015721 Nlrp5 ENSMUSG00000034681 Rnps1 
ENSMUSG00000015937 H2afy ENSMUSG00000034868 Myl12b 
ENSMUSG00000016427 Ndufa1 ENSMUSG00000034928 Rnf44 
ENSMUSG00000016528 Mapkapk2 ENSMUSG00000035027 Map2k2 
ENSMUSG00000016554 Eif3d ENSMUSG00000035086 Becn1 
ENSMUSG00000017390 Aldoc ENSMUSG00000035112 Wnk4 
ENSMUSG00000017404 Rpl19 ENSMUSG00000035354 Uvrag 
ENSMUSG00000017428 Psmd11 ENSMUSG00000035885 Cox8a 
ENSMUSG00000017652 Cd40 ENSMUSG00000036111 Lmo1 
ENSMUSG00000018287 Spag7 ENSMUSG00000036606 Plxnb2 
ENSMUSG00000018326 Ywhab ENSMUSG00000036712 Cyld 
ENSMUSG00000018340 Anxa6 ENSMUSG00000036721 Zscan12 
ENSMUSG00000018537 Pcgf2 ENSMUSG00000036751 Cox6b1 
ENSMUSG00000018559 Ctdnep1 ENSMUSG00000037152 Ndufc1 
ENSMUSG00000018567 Gabarap ENSMUSG00000037206 Islr 
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ENSMUSG00000018697 Aatf ENSMUSG00000037337 Map4k1 
ENSMUSG00000018770 Atp5g3 ENSMUSG00000037362 Nov 
ENSMUSG00000018965 Ywhah ENSMUSG00000037373 Ctbp1 
ENSMUSG00000019087 Atp6ap1 ENSMUSG00000037563 Rps16 
ENSMUSG00000019210 Atp6v1e1 ENSMUSG00000037646 Vps13b 
ENSMUSG00000019461 Plscr3 ENSMUSG00000037706 Cd81 
ENSMUSG00000019494 Cops6 ENSMUSG00000037788 Vopp1 
ENSMUSG00000019804 Snx3 ENSMUSG00000037916 Ndufv1 
ENSMUSG00000019889 Ptprk ENSMUSG00000038346 Zfp384 
ENSMUSG00000020122 Egfr ENSMUSG00000038366 Lasp1 
ENSMUSG00000020149 Rab1 ENSMUSG00000038462 Uqcrfs1 
ENSMUSG00000020163 Uqcr11 ENSMUSG00000038489 Polr2l 
ENSMUSG00000020267 Hint1 ENSMUSG00000038502 Ptov1 
ENSMUSG00000020287 Mpg ENSMUSG00000038612 Mcl1 
ENSMUSG00000020321 Mdh1 ENSMUSG00000038618 Rassf7 
ENSMUSG00000020358 Hnrnpab ENSMUSG00000038619 Ensa 
ENSMUSG00000020368 Canx ENSMUSG00000038650 Rnh1 
ENSMUSG00000020372 Gnb2l1 ENSMUSG00000038690 Atp5j2 
ENSMUSG00000020395 Itk ENSMUSG00000038909 Myst2 
ENSMUSG00000020440 Arf5 ENSMUSG00000038970 Lmtk2 
ENSMUSG00000020444 Guk1 ENSMUSG00000039105 Atp6v1g1 
ENSMUSG00000020458 Rtn4 ENSMUSG00000039195 1110008P14Rik 
ENSMUSG00000020484 Xbp1 ENSMUSG00000039205 Ciz1 
ENSMUSG00000020538 Srebf1 ENSMUSG00000039262 Prrc2b 
ENSMUSG00000020580 Rock2 ENSMUSG00000039452 Snx22 
ENSMUSG00000020673 Tpo ENSMUSG00000039488 Cntn5 
ENSMUSG00000020695 Mrc2 ENSMUSG00000039831 Arhgap29 
ENSMUSG00000020716 Nf1 ENSMUSG00000039852 Rere 
ENSMUSG00000020738 Sumo2 ENSMUSG00000039953 Clstn1 
ENSMUSG00000020821 Kif1c ENSMUSG00000040158 Tax1bp3 
ENSMUSG00000020850 Prpf8 ENSMUSG00000040488 Ltbp4 
ENSMUSG00000021025 Nfkbia ENSMUSG00000040521 Tsfm 
ENSMUSG00000021037 Ahsa1 ENSMUSG00000040537 Adam22 
ENSMUSG00000021127 Zfp36l1 ENSMUSG00000040614 Nlrp9c 
ENSMUSG00000021144 Mta1 ENSMUSG00000040687 Madd 
ENSMUSG00000021218 Gdi2 ENSMUSG00000040836 Gpr161 
ENSMUSG00000021376 Tpmt ENSMUSG00000041075 Fzd7 
ENSMUSG00000021466 Ptch1 ENSMUSG00000041126 H2afv 
 75 
 
ENSMUSG00000021518 Ptdss1 ENSMUSG00000041237 Pklr 
ENSMUSG00000021576 Pdcd6 ENSMUSG00000041278 Ttc1 
ENSMUSG00000021577 Sdha ENSMUSG00000041355 Ssr2 
ENSMUSG00000021614 Vcan ENSMUSG00000041596 Vmn1r90 
ENSMUSG00000021877 Arf4 ENSMUSG00000041881 Ndufa7 
ENSMUSG00000021978 Extl3 ENSMUSG00000041939 Mvk 
ENSMUSG00000022100 Xpo7 ENSMUSG00000042406 Atf4 
ENSMUSG00000022105 Rb1 ENSMUSG00000043079 Synpo 
ENSMUSG00000022174 Dad1 ENSMUSG00000045284 Dcaf12l1 
ENSMUSG00000022194 Pabpn1 ENSMUSG00000045569 Mc2r 
ENSMUSG00000022212 Cpne6 ENSMUSG00000046449 C77370 
ENSMUSG00000022223 Sdr39u1 ENSMUSG00000046865 Fbl 
ENSMUSG00000022285 Ywhaz ENSMUSG00000046982 Tshz1 
ENSMUSG00000022311 Csmd3 ENSMUSG00000047547 Cltb 
ENSMUSG00000022433 Csnk1e ENSMUSG00000047649 Cd3eap 
ENSMUSG00000022443 Myh9 ENSMUSG00000047945 Marcksl1 
ENSMUSG00000022471 Xrcc6 ENSMUSG00000048076 Arf1 
ENSMUSG00000022521 Crebbp ENSMUSG00000048154 Mll2 
ENSMUSG00000022561 Gpaa1 ENSMUSG00000048578 Mlec 
ENSMUSG00000022570 Tsta3 ENSMUSG00000048930 Tada3 
ENSMUSG00000022672 Prkdc ENSMUSG00000048960 Prex2 
ENSMUSG00000022841 Ap2m1 ENSMUSG00000050310 Rictor 
ENSMUSG00000022884 Eif4a2 ENSMUSG00000050824 Sstr5 
ENSMUSG00000022982 Sod1 ENSMUSG00000050856 Atp5k 
ENSMUSG00000023010 Tmbim6 ENSMUSG00000050926 Dcaf12l2 
ENSMUSG00000023175 Bsg ENSMUSG00000051306 Usp42 
ENSMUSG00000023903 Mmp25 ENSMUSG00000051747 Ttn 
ENSMUSG00000023944 Hsp90ab1 ENSMUSG00000051853 Arf3 
ENSMUSG00000024073 Birc6 ENSMUSG00000052026 Slc6a7 
ENSMUSG00000024121 Atp6v0c ENSMUSG00000052397 Ezr 
ENSMUSG00000024213 Nudt3 ENSMUSG00000052423 B4galt3 
ENSMUSG00000024248 Cox7a2l ENSMUSG00000052429 Prmt1 
ENSMUSG00000024346 Pfdn1 ENSMUSG00000052681 Rap1b 
ENSMUSG00000024456 Diap1 ENSMUSG00000052713 Zfp608 
ENSMUSG00000024483 Ankhd1 ENSMUSG00000052957 Gas1 
ENSMUSG00000024525 Impa2 ENSMUSG00000053141 Ptprt 
ENSMUSG00000024527 Afg3l2 ENSMUSG00000053399 Adamts18 
ENSMUSG00000024613 Tcof1 ENSMUSG00000053560 Ier2 
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ENSMUSG00000024639 Gnaq ENSMUSG00000053565 Eif3k 
ENSMUSG00000024646 Cyb5 ENSMUSG00000054102 Nlrp9a 
ENSMUSG00000024767 Otub1 ENSMUSG00000054252 Fgfr3 
ENSMUSG00000024792 Zfpl1 ENSMUSG00000054452 Aes 
ENSMUSG00000024824 Rad9 ENSMUSG00000055022 Cntn1 
ENSMUSG00000024826 Dpf2 ENSMUSG00000055681 Cope 
ENSMUSG00000024830 Rps6kb2 ENSMUSG00000057177 Gsk3a 
ENSMUSG00000024851 Pitpnm1 ENSMUSG00000057278 Snrpg 
ENSMUSG00000024858 Adrbk1 ENSMUSG00000058454 Dhcr7 
ENSMUSG00000024914 Drap1 ENSMUSG00000058558 Rpl5 
ENSMUSG00000024927 Rela ENSMUSG00000058569 Tmed9 
ENSMUSG00000024944 Arl2 ENSMUSG00000058655 Eif4b 
ENSMUSG00000024962 Vegfb ENSMUSG00000059070 Rpl18 
ENSMUSG00000025130 P4hb ENSMUSG00000059447 Hadhb 
ENSMUSG00000025132 Arhgdia ENSMUSG00000059518 Znhit1 
ENSMUSG00000025231 Sufu ENSMUSG00000059552 Trp53 
ENSMUSG00000025321 Itgb8 ENSMUSG00000059708 Akap17b 
ENSMUSG00000025366 Esyt1 ENSMUSG00000060429 Sntb1 
ENSMUSG00000025381 Cnpy2 ENSMUSG00000060508 Nlrp9b 
ENSMUSG00000025428 Atp5a1 ENSMUSG00000060680 Gm8894 
ENSMUSG00000025474 Tubgcp2 ENSMUSG00000060802 B2m 
ENSMUSG00000025499 Hras1 ENSMUSG00000061315 Naca 
ENSMUSG00000025503 Taldo1 ENSMUSG00000061462 Obscn 
ENSMUSG00000025508 Rplp2 ENSMUSG00000061904 Slc25a3 
ENSMUSG00000025651 Uqcrc1 ENSMUSG00000062070 Pgk1 
ENSMUSG00000025743 Sdc3 ENSMUSG00000062284 Gm6030 
ENSMUSG00000025745 Hadha ENSMUSG00000062825 Actg1 
ENSMUSG00000025793 Hgs ENSMUSG00000062867 Impdh2 
ENSMUSG00000025892 Gria4 ENSMUSG00000063229 Ldha 
ENSMUSG00000026024 Als2 ENSMUSG00000063239 Grm4 
ENSMUSG00000026209 Dnpep ENSMUSG00000063410 Stk24 
ENSMUSG00000026276 Sept2 ENSMUSG00000063457 Rps15 
ENSMUSG00000026395 Ptprc ENSMUSG00000063511 Snrnp70 
ENSMUSG00000026450 Chit1 ENSMUSG00000063870 Chd4 
ENSMUSG00000026750 Psmb7 ENSMUSG00000063882 Uqcrh 
ENSMUSG00000026786 Apbb1ip ENSMUSG00000064068 Mtx1 
ENSMUSG00000026842 Abl1 ENSMUSG00000065954 Tacc1 
ENSMUSG00000026864 Hspa5 ENSMUSG00000066306 Numa1 
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ENSMUSG00000026976 Pax8 ENSMUSG00000067150 Xpo5 
ENSMUSG00000027193 Api5 ENSMUSG00000067657 AC124479.2 
ENSMUSG00000027223 Mapk8ip1 ENSMUSG00000067713 Prkag1 
ENSMUSG00000027224 Duoxa1 ENSMUSG00000068206 Pick1 
ENSMUSG00000027247 Arhgap1 ENSMUSG00000068267 Cenpb 
ENSMUSG00000027276 Jag1 ENSMUSG00000070319 Eif3g 
ENSMUSG00000027367 Stard7 ENSMUSG00000071054 Safb 
ENSMUSG00000027404 Snrpb ENSMUSG00000071076 Jund 
ENSMUSG00000027406 Idh3b ENSMUSG00000071531 Gprin2 
ENSMUSG00000027422 Rrbp1 ENSMUSG00000071645 Tut1 
ENSMUSG00000027523 Gnas ENSMUSG00000071650 Ganab 
ENSMUSG00000027566 Psma7 ENSMUSG00000073226 Gm10482 
ENSMUSG00000027665 Pik3ca ENSMUSG00000073640 Rpl27-ps3 
ENSMUSG00000027852 Nras ENSMUSG00000073802 Cdkn2b 
ENSMUSG00000027937 Jtb ENSMUSG00000074034 Gm5921 
ENSMUSG00000027944 Hax1 ENSMUSG00000074305 C230081A13Rik 
ENSMUSG00000027951 Adar ENSMUSG00000074643 Cpne1 
ENSMUSG00000028039 Efna3 ENSMUSG00000075706 Gpx4 
ENSMUSG00000028041 Adam15 ENSMUSG00000076432 Ywhaq 
ENSMUSG00000028049 Scamp3 ENSMUSG00000078676 Casc3 
ENSMUSG00000028140 Mrpl9 ENSMUSG00000079426 Arpc4 
ENSMUSG00000028289 Epha7 ENSMUSG00000079523 Tmsb10 
ENSMUSG00000028312 Smc2 ENSMUSG00000089986 Ankhd1-Eif4ebp3 
ENSMUSG00000028367 Txn1 ENSMUSG00000090247 Bloc1s1 
I designed the custom bait library by using Agilent SureDesign. The whole gene regions of 
these 500 genes, including the both exon and intron, were targeted. The genes which listed in 
the COSMIC: Cancer Gene Census were highlighted in red. 
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Supplementary Table S2.2. Details of 83 mutation candidate positions. 
position 
Normalized VAF Annotation 
Papi 
9w 
Papi 
14w 
Carc Meta 
Reg 
9w 
Reg 
14w 
Effect GeneID 
7:141192550 0.4999 0.5001 0.5001 0.5000 0.5001 0.5001 Missense Hras1 
2:98662257 0.0259 0.0197 0.0611 0.0000 0.0224 0.0268 Synonymous Gm10801 
2:98662457 0.0396 0.0000 0.0442 0.1711 0.0205 0.0453 Missense Gm10801 
9:3000377 0.0368 0.0403 0.0330 0.2766 0.0289 0.0362 Upstream Gm10722 
2:98662399 0.0302 0.0197 0.0696 0.1822 0.0274 0.0472 Missense Gm10801 
9:35305329 0.0222 0.0108 0.0752 0.2000 0.0204 0.0420 Intergenic - 
9:35305343 0.0237 0.0254 0.0342 0.0862 0.0154 0.0257 Intergenic - 
2:98665129 0.0284 0.0220 0.0451 0.1162 0.0191 0.0432 Downstream Gm10800 
X:163478989 0.0369 0.0205 0.0568 0.0992 0.0138 0.0421 Others Gm7199 
2:98662293 0.0199 0.0090 0.0360 0.1926 0.0138 0.0183 Synonymous Gm10801 
2:98666287 0.0213 0.0071 0.0483 0.0940 0.0269 0.0282 Downstream Gm10800 
2:98662411 0.0000 0.0126 0.0592 0.1174 0.0186 0.0257 Missense Gm10801 
2:98662805 0.0000 0.0505 0.0348 0.2408 0.0271 0.0765 Downstream Gm10800 
14:19417883 0.0441 0.0000 0.0000 0.2345 0.0152 0.0213 Intron AC242409.1 
9:3025531 0.0000 0.0000 0.0000 0.2437 0.0277 0.0461 Missense Gm10716 
1:181187046 0.0000 0.0390 0.0000 0.1644 0.0164 0.0000 Upstream Wdr26 
9:3002159 0.0000 0.0391 0.0692 0.0000 0.0177 0.0198 Upstream Gm11168 
9:3002107 0.0000 0.0567 0.0000 0.0000 0.0149 0.0188 Upstream Gm11168 
9:3002141 0.0000 0.0337 0.0000 0.0000 0.0206 0.0211 Upstream Gm11168 
14:65077037 0.0130 0.0040 0.0000 0.0179 0.0042 0.0000 Missense Extl3 
19:8766798 0.0109 0.0000 0.0000 0.0259 0.0036 0.0000 Missense Nxf1 
18:15414888 0.0000 0.3858 0.1519 0.0000 0.0000 0.0000 Intergenic - 
5:10957983 0.0000 0.2231 0.0865 0.0000 0.0000 0.0000 Intron Gm5152 
1:138067914 0.0000 0.3376 0.2823 0.3540 0.0000 0.0000 Nonsense Ptprc 
15:79144413 0.0000 0.3357 0.3370 0.3548 0.0000 0.0000 Intron Polr2f 
2:76896947 0.0000 0.3243 0.1524 0.1359 0.0000 0.0000 Missense Ttn 
5:84866414 0.0000 0.2879 0.1527 0.1341 0.0000 0.0000 Intergenic - 
14:69159185 0.0000 0.2684 0.1377 0.1117 0.0000 0.0000 Intergenic - 
7:39662651 0.0000 0.2042 0.1498 0.1171 0.0000 0.0000 Intergenic - 
12:30092627 0.0000 0.2944 0.1371 0.1996 0.0000 0.0000 Synonymous Tpo 
8:88710071 0.0000 0.3413 0.1442 0.1922 0.0000 0.0000 Intron Cyld 
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10:29781362 0.0000 0.4175 0.1781 0.1993 0.0000 0.0000 Intergenic - 
19:5647309 0.0000 0.3744 0.1837 0.2367 0.0000 0.0000 Missense Rela 
4:43554186 0.0000 0.3647 0.2011 0.1795 0.0000 0.0000 Upstream Tln1 
9:88454294 0.0000 0.3259 0.2016 0.1928 0.0000 0.0000 Intron Gm20537 
2:76807228 0.0000 0.3395 0.1745 0.1402 0.0000 0.0000 Intron Ttn 
2:91178303 0.0000 0.3282 0.1876 0.1712 0.0000 0.0000 Missense Madd 
4:28817318 0.0000 0.3509 0.1860 0.1568 0.0000 0.0000 Intron Epha7 
15:35705682 0.0000 0.0000 0.0213 0.0000 0.0000 0.0000 Intron Vps13b 
17:12247878 0.0000 0.0000 0.0755 0.0000 0.0000 0.0000 Intron Map3k4 
8:43289942 0.0000 0.0000 0.0438 0.0000 0.0000 0.0000 Intergenic - 
15:89160554 0.0000 0.0000 0.0000 0.1282 0.0000 0.0000 Upstream Plxnb2 
11:120346973 0.0000 0.0000 0.0405 0.1253 0.0000 0.0000 Missense Actg1 
11:120346787 0.0000 0.0000 0.0123 0.0570 0.0000 0.0000 Synonymous Actg1 
8:100030643 0.0000 0.0000 0.0153 0.0672 0.0000 0.0000 Others Gm15210 
2:76787076 0.0000 0.0000 0.0000 0.0000 0.3917 0.4303 Synonymous Ttn 
6:125218819 0.0000 0.0000 0.0000 0.0000 0.3908 0.3274 Intron Vamp1 
12:18013571 0.0000 0.0000 0.0000 0.0000 0.3883 0.3083 Intergenic - 
15:98864350 0.0000 0.0000 0.0000 0.0000 0.3936 0.3162 Synonymous Mll2 
16:15833961 0.0000 0.0000 0.0000 0.0000 0.4440 0.3818 Intron Prkdc 
2:76738847 0.0000 0.0000 0.0000 0.0000 0.4521 0.3405 Missense Ttn 
9:62842036 0.0000 0.0068 0.0000 0.0000 0.0046 0.0000 Upstream Cln6 
7:17139272 0.0000 0.0000 0.0000 0.0000 0.0357 0.0000 Intergenic - 
11:55004766 0.0000 0.0000 0.0000 0.0000 0.0083 0.0000 Intron Anxa6 
11:69588515 0.0000 0.0000 0.0000 0.0000 0.0127 0.0000 Missense Trp53 
13:98853314 0.1033 0.0425 0.0000 0.0000 0.0000 0.0513 Intron Tnpo1 
2:76766295 0.0158 0.0062 0.0000 0.0000 0.0000 0.0229 Missense Ttn 
4:148550842 0.0208 0.0166 0.0000 0.0000 0.0000 0.0502 
Downstream/
Upstream 
Mtor/ 
U6 
11:79436839 0.0000 0.0119 0.0000 0.0000 0.0000 0.0462 Intron Nf1 
12:21394815 0.0000 0.0572 0.0000 0.0000 0.0000 0.1283 Downstream Ywhaq 
2:108948762 0.0324 0.0000 0.0000 0.0000 0.0000 0.0739 Upstream Gm13910 
6:133762795 0.0939 0.0000 0.0000 0.0000 0.0000 0.0770 Upstream AC122359.1 
11:59067729 0.0000 0.0000 0.0000 0.0000 0.0000 0.0132 Missense Obscn 
3:89141498 0.0000 0.0000 0.0000 0.0000 0.0000 0.0131 Intron Pklr 
4:101161963 0.0000 0.0000 0.0000 0.0000 0.0000 0.0597 Intron Jak1 
 80 
 
7:21230248 0.0000 0.0000 0.0000 0.0000 0.0000 0.0687 Intergenic - 
17:46215562 0.0000 0.0465 0.0000 0.0000 0.0000 0.0000 Intron Xpo5 
2:76861409 0.0000 0.0121 0.0000 0.0000 0.0000 0.0000 Intron Ttn 
7:13030561 0.0000 0.0064 0.0000 0.0000 0.0000 0.0000 Missense Trim28 
18:60828610 0.0000 0.0074 0.0000 0.0639 0.0000 0.0000 Intron Tcof1 
3:99500989 0.0000 0.0101 0.0000 0.0203 0.0000 0.0000 Others M6pr-ps 
15:90723932 0.2446 0.0000 0.0000 0.0000 0.0000 0.0000 Intergenic - 
2:76825807 0.4816 0.0000 0.0000 0.0000 0.0000 0.0000 Missense Ttn 
10:79710761 0.4756 0.0000 0.0000 0.0000 0.0000 0.0000 Missense Bsg 
6:107881483 0.4772 0.0000 0.0000 0.0000 0.0000 0.0000 Intergenic - 
2:76846783 0.4504 0.0000 0.0000 0.0000 0.0000 0.0000 Synonymous Ttn 
14:55514768 0.4244 0.0000 0.0000 0.0000 0.0000 0.0000 Downstream Cpne6/Nrl 
4:28966425 0.4303 0.0000 0.0000 0.0000 0.0000 0.0000 3'UTR Epha7 
12:31018401 0.0187 0.0000 0.0000 0.0000 0.0000 0.0000 Intergenic - 
6:122696935 0.0597 0.0000 0.0000 0.0000 0.0000 0.0000 Downstream Gm10420 
X:110604447 0.1181 0.0000 0.0000 0.0000 0.0000 0.0000 Downstream Gm14886 
10:88247930 0.0437 0.0484 0.0000 0.0000 0.0000 0.0000 Downstream Ccdc53 
8:33615918 0.0226 0.0154 0.0000 0.0000 0.0000 0.0000 Intron Ppp2cb 
The normalized VAFs of each tumor sample, the effect of the mutation, and the genes 
including the position are shown. The order corresponds to Fig. 2.1b. 
 
